Resultados del 1er trimestre
Renk AG
n / a
07:46 20/03/24
AstraZeneca
25 de abril de 2024
Resultados de Q1 2024
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Resumen de ingresos y EPS
Q1 2024 | % Cambio | |||||||
|
| $m | Real | CER[ 1 ] |
| |||
- Venta de productos | 12,177 | 15 | 18 |
| ||||
- Ingresos de la Alianza | 457 | 59 | 59 |
| ||||
- Ingresos por colaboración | 45 | 66 | 66 |
| ||||
Los ingresos totales | 12,679 | 17 | 19 |
| ||||
EPS reportado | $1.41 | 21 | 30 |
| ||||
Core[ 2 ] EPS | $2.06 | 7 | 13 |
| ||||
Financial performance for Q1 2024 (GRowth números en CER)
- Total Revenue up 19% to $12,679m, driven by an 18% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines
- Double-digit growth in Total Revenue from Oncology at 26%, CVRM at 23%, R&I at 17%, and Rare Disease at 16%.
- Margen bruto de ventas de productos principales[ 3 ] de 82%
- Core Operating Margin of 34%
- Core Tax Rate of 21%
- Core EPS increased 13% to $2.06. The increase in Core EPS was lower than Total Revenue growth principally due to a $241m gain in the prior year period on the disposal of Pulmicort Flexhaler® US rights
- As announced at the Annual General Meeting on 11 April 2024, the total dividend for FY 2024 will increase by $0.20 per share to $3.10 per share
- Total Revenue and Core EPS guidance at CER for FY 2024 reiterated
Pascal Soriot, director ejecutivo de AstraZeneca, dijo:
"AstraZeneca had a very strong start in 2024 with substantial Total Revenue growth of 19% in the first quarter.
Our strong pipeline momentum continued and already this year we announced positive trial results for Imfinzi and Tagrisso that were unprecedented in lung cancer, the data from both of these studies will be presented during the ASCO plenary in June. We are also looking forward to seeing the results of several other important trials throughout the year.
At our Annual General Meeting we were pleased to announce a 7% increase in the annual dividend, and at our Investor Day on 21 May 2024 we will outline the evolution of our company, underscoring our confidence in sustaining industry-leading growth."
Hitos clave alcanzados desde el anuncio de resultados anterior
- Positive read-outs for Tagrisso in unresectable, Stage III EGFRm NSCLC (LAURA), Imfinzi in LS-SCLC (ADRIATIC)
- US approvals for Tagrisso with the addition of chemotherapy for EGFRm NSCLC (FLAURA2), Enhertu in HER2-positive solid tumours (DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02) and Ultomiris for NMOSD. US and EU approval for Voydeya as an add-on therapy a Ultomiris or Soliris for PNH with EVH (ALPHA). Japan approval for Truqap más Faslodex in unresectable or recurrent PIK3CA-, AKT1- o PTEN-altered HR-positive, HER2-negative breast cancer (CAPItello-291).
- Datopotamab deruxtecan BLAs accepted in the US for non-squamous NSCLC (TROPION-Lung01) and HR-positive, HER2-negative breast cancer (TROPION-Breast01).
Dirección
The Company reiterates its Total Revenue and Core EPS guidance for FY 2024 at CER, based on the average foreign exchange rates through 2023.
Total Revenue is expected to increase by a low double-digit to low teens percentage
Core EPS is expected to increase by a bajo double-digit to low teens percentage
- Collaboration Revenue is expected to increase substantially, driven by success-based milestones and certain anticipated transactions
- Other operating income is expected to decrease substantially (FY 2023 included a $241m gain on the disposal of Pulmicort Flexhaler® US rights, and a $712m one-time gain relating to updates to contractual arrangements for beyfortus)
- The Core Tax rate is expected to be between 18-22%
La Compañía no puede proporcionar orientación sobre una base reportada porque no puede pronosticar de manera confiable elementos materiales de los resultados reportados, incluidos los ajustes del valor razonable que surjan de pasivos relacionados con adquisiciones, cargos por deterioro de activos intangibles y disposiciones de liquidación legal. Consulte la sección de declaraciones de precaución sobre declaraciones prospectivas al final de este anuncio.
Impacto de la moneda
If foreign exchange rates for April 2024 to December 2024 were to remain at the average rates seen in March 2024, compared to the performance at CER it is anticipated that FY 2024 Total Revenue would incur a low single-digit adverse impact and Core EPS would incur a mid single-digit adverse impact (previously low single-digit). The Company's foreign exchange rate sensitivity analysis is provided in Table 16.
Día del inversor
AstraZeneca will host an Investor Day on 21 May 2024. For more information, see www.astrazeneca.com/investor-relations.html.
Mesa 1: Elementos clave del desempeño de los ingresos totales en el segundo trimestre de 1
| % Cambio |
|
|
Tipo de ingresos | $m | % Real | CER% |
|
| |
Venta de productos | 12,177 | 15 | 18 | |||
Ingresos de la Alianza | 457 | 59 | 59 | * $ 339m Enhertu (segundo trimestre de 1: 2023 millones de dólares) * $ 77m Tezspire (segundo trimestre de 1: 2023 millones de dólares) | ||
Ingresos por colaboración | 45 | 66 | 66 | * $ 45m Farxiga (segundo trimestre de 1: 2023 millones de dólares) | ||
Los ingresos totales | 12,679 | 17 | 19 | |||
Áreas de terapia | $m | Actual % | % RCE |
|
| |
Oncología | 5,108 | 23 | 26 | * Strong performance across all key medicines and regions | ||
CVRM | 3,060 | 20 | 23 |
| * Farxiga up 43% (45% at CER) with continued demand growth and the launch of an authorised generic in the US, Lokelma up 16% (19% at CER), roxadustat up 24% (28% at CER), Brilinta decreased 3% (1% at CER) | |
RHODE ISLAND | 1,886 | 15 | 17 | * Continued strong growth from fasenra hasta un 6% (6% CER), Breztri hasta un 52% (54% CER). saphnelo up 94% (95% CER) and Tezspire up >2x (>2x CER). SYMBICORT® was up 12% (14% CER) | ||
V&I | 232 | (35) | (34) | * beyfortus revenue was $46m (Q1 2023: $nil), which more than offset a $27m decline in Synagis * The drop in V&I revenue was driven by lower sales of COVID-19 mAbs and Vaxzevria. Vaxzevria revenues are now included in the 'Other' V&I line | ||
Enfermedad rara | 2,096 | 12 | 16 | * Ultomiris aumento del 32% (34% a CER), parcialmente compensado por la caída en Soliris del 11% (8% a CER) * Strensiq hasta un 20% (21% a CER) y Koselugo up 68% (82% at CER) reflecting strong patient demand, and also tender market order timing | ||
Otros medicamentos | 297 | (7) | - | |||
Los ingresos totales | 12,679 | 17 | 19 | |||
Regiones | $m | Actual % | % RCE |
|
| |
US | 5,124 | 19 | 19 | |||
Mercados Emergentes | 3,732 | 18 | 26 | |||
- China, |
| 1,748 | 9 | 13 |
|
|
- Mercados emergentes excepto China |
| 1,984 | 27 | 40 |
|
|
Europa | 2,634 | 22 | 19 | |||
DdV establecido | 1,189 | (5) | 2 | * Decline in COVID-19 mAbs revenue | ||
Los ingresos totales | 12,679 | 17 | 19 |
ventas combinadas de Enhertu, recorded by Daiichi Sankyo Company Limited (Daiichi Sankyo) and AstraZeneca, amounted to $879m in Q1 2024 (Q1 2023: $531m).
ventas combinadas de Tezspire, recorded by Amgen and AstraZeneca, amounted to $216m in Q1 2024 (Q1 2023: $105m).
Mesa 2: Elementos clave del desempeño financiero en el segundo trimestre de 1
Métricos | reportado | Cambio informado | Core | Core | Comentarios[ 4 ] | |
Los ingresos totales | $ 12,679m | 17% Real 19% CER | $ 12,679m | 17% Real 19% CER | * Consulte la Tabla 1 y la sección Ingresos totales de este documento para obtener más detalles. | |
Margen bruto de ventas de productos | 82% | Estable | 82% | -1pp Actual -1pp CER | * Se pueden esperar variaciones en el margen bruto de ventas de productos entre períodos debido a la estacionalidad del producto, fluctuaciones cambiarias y otros efectos. | |
Gastos de I + D | $ 2,783m | 7% Real 7% CER | $ 2,698m | 17% Real 18% CER | + Increased investment in the pipeline * Relación principal de I+D e ingresos totales del 21% | |
gastos de venta, generales y administrativos | $ 4,495m | 11% Real 12% CER | $ 3,413m | 12% Real 13% CER | + Market development for recent launches and pre-launch activities * Relación de gastos generales, administrativos y de ingresos totales del 27 % | |
Otros ingresos y gastos operativos[ 5 ] | $ 67m | -83% Real -83% CER | $ 65m | -80% Real -80% CER | - The prior year quarter included a $241m gain on the disposal of Pulmicort flexhaler US rights | |
Margen operativo | 25% | +1pp Real +2pp CER | 34% | -2pp Actual -1pp CER | * See commentary above on Other operating income and expense | |
Gastos financieros netos | $ 302m | 5% Real 1% CER | $ 245m | 2% Actual -3% CER | + Higher rates on floating debt and bond issuances - Higher interest received on cash and short-term investments | |
Tasa de impuesto | 22% | +2pp Real +2pp CER | 21% | +2pp Real +2pp CER | * Se pueden esperar variaciones en la tasa impositiva entre períodos. | |
EPS | $1.41 | 21% Real 30% CER | $2.06 | 7% Real 13% CER | * En la Tabla 11 se muestran más detalles de las diferencias entre Reported y Core. |
Mesa 3: Aspectos destacados de la cartera desde el anuncio de resultados anterior
Evento | Medicina | Indicación / Prueba
| Evento |
Aprobaciones regulatorias y otras acciones regulatorias | Enhertu | HER2-expressing tumours (DESTINY-PanTumor02) | Aprobación reglamentaria (EE. UU.) |
Tagrisso | EGFRm NSCLC (1st-line) (FLAURA2) | Aprobación reglamentaria (EE. UU.) | |
Truqap | HR+/HER2-neg breast cancer (2nd-line) (CAPItello-291) | Aprobación reglamentaria (JP) | |
beyfortus | RSV (MELODY-MEDLEY) | Aprobación reglamentaria (JP) | |
Ultomiris | NMOSD (CHAMPION-NMOSD) | Aprobación reglamentaria (EE. UU.) | |
Voydeya | PNH with EVH (ALPHA) | Regulatory approval (US, EU) | |
Presentaciones regulatorias | Dado-DXd | Non-squamous NSCLC (2nd- and 3rd-line) (TROPION-Lung01) | Presentación reglamentaria (EE. UU.) |
Dado-DXd | HR+/HER2- breast cancer (inoperable and/or met.) (TROPION-Breast01) | Regulatory submission (US, EU, JP, CN) | |
acoramidis | ATTR-CM (ALXN2060-TAC-302) | Presentación reglamentaria (JP) | |
|
|
| |
Principales lecturas de datos de la Fase III y otros desarrollos | Tagrisso | EGFRm NSCLC (estadio III no resecable) (LAURA) | Criterio de valoración principal cumplido |
Imfinzi | SCLC (limited-stage) (ADRIATIC) | Criterio de valoración principal cumplido |
*La presentación reglamentaria de EE. UU., la UE y China indica la aceptación de la presentación
Próximos catalizadores de tuberías
For recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix, available on www.astrazeneca.com/investor-relations.html.
Desarrollo corporativo y empresarial
In February 2024, AstraZeneca completed the acquisition of Gracell Biotechnologies, Inc. (Gracell), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases. The acquisition enriches AstraZeneca's growing pipeline of cell therapies with AZD0120 (formerly GC012F), a novel, clinical-stage T-cell (CAR-T) therapy. AZD0120 is a potential new treatment for multiple myeloma, as well as other haematologic malignancies and autoimmune diseases, including SLE. The upfront cash portion of the consideration was approximately $1.0 billion. Combined, the upfront and potential contingent value payments represent, if achieved, a transaction value of approximately $1.2 billion. AstraZeneca acquired the cash and cash equivalents on Gracell's balance sheet, which totalled $209 million at the close of the transaction.
In February 2024, AstraZeneca completed the acquisition of Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle platform. The upfront cash portion of the consideration was approximately $0.8 billion. Combined, the upfront and maximum potential contingent value payments represent, if achieved, a transaction value of approximately $1.1 billion. AstraZeneca acquired the cash, cash equivalents and marketable securities on Icosavax's balance sheet, which totalled $192 million at the close of the transaction.
In March 2024, AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. The proposed acquisition will bolster the Rare Disease late-stage pipeline and expand on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism. The upfront cash portion of the consideration is $0.8 billion at deal closing. Combined, the upfront and maximum potential contingent value payments represent, if achieved, a transaction value of $1.05 billion. AstraZeneca will acquire all of Amolyt Pharma's outstanding shares on a cash and debt free basis. Subject to the satisfaction of customary closing conditions in the acquisition agreement, including regulatory clearances, the transaction is expected to close by the end of the third quarter of 2024.
In March 2024, AstraZeneca entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates. This complements AstraZeneca's leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most advanced programme, FPI-2265, a potential new treatment for patients with mCRPC. The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. The upfront cash portion of the consideration is approximately $2 billion. Combined, the upfront and maximum potential contingent value payments represent, if achieved, a transaction value of approximately $2.4 billion. AstraZeneca will acquire the cash, cash equivalents and short term investments on Fusion's balance sheet, which totalled $234 million as of 31 December 2023. The transaction is expected to close in the second quarter of 2024, subject to customary closing conditions, including the approval of Fusion shareholders and regulatory clearances.
Aspectos destacados de la sostenibilidad
Our newly announced collaboration with China Resources Gas and Everbright Environment will supply biomethane and biomethane-based steam to our Wuxi site. Using domestic waste, including food and plant waste, this new partnership will enable us to reduce our greenhouse gas emissions footprint by 80% in China.
AstraZeneca announced at WEF that it will be one of the inaugural Early Adopter organisations that intend to start making disclosures aligned with the Taskforce on Nature-related Financial Disclosures Recommendations in corporate reporting.
AstraZeneca also hosted an annual Sustainability call for shareholders, reiterating its continued commitment to deliver across our pillars; Access to Healthcare, Environmental Protection and Ethics and Transparency. A recording of the call and accompanying materials are available on the AstraZeneca IR website.
Conferencia
A conference call and webcast for investors and analysts will begin today, 25 April 2024, at 11:45 UK time. Details can be accessed via astrazeneca.com.
Calendario de informes
The Company intends to publish its H1 and Q2 2024 results on 25 July 2024.
Revisión operativa y financiera
All narrative on growth and results in this section is based on actual exchange rates, and financial figures are in US$ millions ($m), unless stated otherwise. Unless stated otherwise, the performance shown in this announcement covers the three month period to 31 March 2024 ('the quarter' or 'Q1 2024') compared to the three month period to 31 March 2023 ('Q1 2023'). References to 'first quarter', 'second quarter', 'third quarter' and fourth quarter' refer to the respective quarters in FY 2024.
Core financial measures, EBITDA, Net debt, Product Sales Gross Margin, Operating Margin and CER are non-GAAP financial measures because they cannot be derived directly from the Group's Condensed consolidated financial statements. Management believes that these non-GAAP financial measures, when provided in combination with Reported results, provide investors and analysts with helpful supplementary information to understand better the financial performance and position of the Group on a comparable basis from period to period. These non-GAAP financial measures are not a substitute for, or superior to, financial measures prepared in accordance with GAAP.
Core financial measures are adjusted to exclude certain significant items:
- Cargos y provisiones relacionados con programas de reestructuración, que incluyen cargos relacionados con el impacto de los programas de reestructuración en los activos de TI capitalizados
- Amortización y deterioro del valor de los activos intangibles, incluidas las reversiones del deterioro pero excluyendo cualquier cargo relacionado con los activos de TI
- Other specified items, principally the imputed finance charges and fair value movements relating to contingent consideration on business combinations, imputed finance charges and remeasurement adjustments on certain Other payables arising from intangible asset acquisitions, legal settlements and remeasurement adjustments relating to Other payables assumed from the Alexion acquisition
- Los efectos fiscales de los ajustes anteriores están excluidos del cargo por impuesto básico.
Los detalles sobre la naturaleza de las medidas financieras básicas se proporcionan en la página 61 del Annual Report and Form 20-F Information 2023.
Se debe hacer referencia a la tabla de conciliación de medidas financieras informadas con las principales incluida en la sección de desempeño financiero de este anuncio.
Product Sales Gross Margin is calculated by dividing the difference between Product Sales and Cost of Sales by the Product Sales. The calculation of Reported and Core Product Sales Gross Margin excludes the impact of Alliance Revenue and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales.
El EBITDA se define como el Beneficio reportado antes de impuestos después de sumar los gastos financieros netos, los resultados de negocios conjuntos y asociadas y los cargos por depreciación, amortización y deterioro. Cabe hacer referencia a la conciliación del beneficio declarado antes de impuestos con el EBITDA incluida en la sección de rendimiento financiero de este anuncio.
El margen operativo se define como beneficio operativo como porcentaje de los ingresos totales.
La deuda neta se define como Préstamos y empréstitos que devengan intereses y Pasivos por arrendamiento, neto de Efectivo y equivalentes de efectivo, Otras inversiones e Instrumentos financieros derivados netos. Cabe hacer referencia a la Nota 3 'Deuda neta' incluida en la Memoria de los estados financieros intermedios de este anuncio.
La Compañía recomienda encarecidamente a los inversionistas y analistas que no se basen en una sola medida financiera, sino que revisen los estados financieros de AstraZeneca, incluidas las Notas correspondientes, y otros informes disponibles de la Compañía, cuidadosamente y en su totalidad.
Debido al redondeo, es posible que la suma de varios valores en dólares y porcentajes en este anuncio no coincida con los totales.
Los ingresos totales
Mesa 4: Total Revenue by therapy area and medicine[ 6 ]
|
| Q1 2024 | ||
|
|
|
| % Cambio |
Los ingresos totales |
| $m | % totales | Real | CER |
Oncología | 5,108 | 40 | 23 | 26 | |
- Tagrisso | 1,595 | 13 | 12 | 15 | |
- Imfinzi | 1,113 | 9 | 29 | 33 | |
- Calcuencia | 718 | 6 | 35 | 35 | |
- lynparza | 705 | 6 | 8 | 11 | |
- Enhertu | 461 | 4 | 79 | 79 | |
- Zoladex | 285 | 2 | 21 | 28 | |
- Imjudo | 62 | - | 66 | 70 | |
- Truqap | 50 | - | Nuevo Méjico | Nuevo Méjico | |
- Orpatías | 12 | - | 43 | 49 | |
- Other Oncology | 107 | 1 | (24) | (19) | |
Biofarmacéuticos: CVRM | 3,060 | 24 | 20 | 23 | |
- Farxiga | 1,892 | 15 | 43 | 45 | |
- Brilinta | 323 | 3 | (3) | (1) | |
- Crestor | 297 | 2 | (3) | 2 | |
- seloken/Toprol-XL | 165 | 1 | (8) | (2) | |
- Lokelma | 114 | 1 | 16 | 19 | |
- roxadustato | 77 | 1 | 24 | 28 | |
- Andexxa | 47 | - | 6 | 6 | |
- Wainua | 5 | - | Nuevo Méjico | Nuevo Méjico | |
- Other CVRM | 141 | 1 | (33) | (31) | |
Biofarmacéuticos: R&I | 1,886 | 15 | 15 | 17 | |
- SYMBICORT® | 769 | 6 | 12 | 14 | |
- fasenra | 358 | 3 | 6 | 6 | |
- Pulmicort | 224 | 2 | 1 | 5 | |
- Breztri | 219 | 2 | 52 | 54 | |
- Tezspire | 120 | 1 | > 2x | > 2x | |
- saphnelo | 91 | 1 | 94 | 95 | |
- Airsupra | 7 | - | Nuevo Méjico | Nuevo Méjico | |
- Other R&I | 98 | 1 | (30) | (29) | |
Biofarmacéuticos: V&I | 232 | 2 | (35) | (34) | |
- Synagis |
| 171 | 1 | (13) | (13) |
- beyfortus |
| 46 | - | Nuevo Méjico | Nuevo Méjico |
- FluMist | 7 | - | > 2x | > 2x | |
- mAb de COVID-19 | 2 | - | (99) | (99) | |
- Other V&I | 6 | - | (79) | (80) | |
Enfermedad rara | 2,096 | 17 | 12 | 16 | |
- Ultomiris | 859 | 7 | 32 | 34 | |
- Soliris | 739 | 6 | (11) | (8) | |
- Strensiq | 313 | 2 | 20 | 21 | |
- Koselugo | 132 | 1 | 68 | 82 | |
- Kanuma | 53 | - | 32 | 35 | |
Otros medicamentos | 297 | 2 | (7) | - | |
- Nexium |
| 243 | 2 | (2) | 7 |
- Otros | 54 | - | (25) | (23) | |
Total Medicines | 12,679 | 100 | 17 | 19 |
Mesa 5: Ingresos de la Alianza
Q1 2024 | |||||
% Cambio | |||||
| $m | % totales | Real | CER | |
Enhertu | 339 | 74 | 54 | 54 | |
Tezspire | 77 | 17 | 80 | 80 | |
beyfortus | 20 | 4 | Nuevo Méjico | Nuevo Méjico | |
Otros ingresos de la Alianza | 21 | 5 | (10) | (9) | |
Total |
| 457 | 100 | 59 | 59 |
Mesa 6: Ingresos de colaboración
Q1 2024 | |||||
| % Cambio | ||||
| $m | % totales | Real | CER | |
Farxiga: hitos de ventas | 45 | 100 | 86 | 86 | |
Otros ingresos por colaboración | - | - | Nuevo Méjico | Nuevo Méjico | |
Total |
| 45 | 100 | 66 | 66 |
Mesa 7: Ingresos totales por área de terapia
Q1 2024 | ||||
% Cambio |
$m | % totales | Real | CER | ||
Oncología | 5,108 | 40 | 23 | 26 | |
Biofarmaceuticos | 5,178 | 41 | 14 | 16 | |
CVRM |
| 3,060 | 24 | 20 | 23 |
RHODE ISLAND |
| 1,886 | 15 | 15 | 17 |
V&I |
| 232 | 2 | (35) | (34) |
Enfermedad rara | 2,096 | 17 | 12 | 16 | |
Otros medicamentos | 297 | 2 | (7) | - | |
Total |
| 12,679 | 100 | 17 | 19 |
Mesa 8: Ingresos totales por región
Q1 2024 | ||||
% Cambio |
$m | % totales | Real | CER | ||
US | 5,124 | 40 | 19 | 19 | |
Mercados Emergentes | 3,732 | 29 | 18 | 26 | |
China |
| 1,748 | 14 | 9 | 13 |
Emerging Markets ex. China |
| 1,984 | 16 | 27 | 40 |
Europa | 2,634 | 21 | 22 | 19 | |
Established ROW | 1,189 | 9 | (5) | 2 | |
Total |
| 12,679 | 100 | 17 | 19 |
Oncología
Oncology Total Revenue of $5,108m in Q1 2024 increased by 23% (26% at CER), representing 40% of overall Total Revenue (Q1 2023: 38%). Product Sales increased by 21% (24% at CER) in Q1 2024 to $4,760m, reflecting new launches and expanded reimbursement across key brands.
Tagrisso
Los ingresos totales | TODO EL MUNDO | US | Mercados Emergentes | Europa | DdV establecido | ||
Q1 2024 $m | 1,595 | 623 | 488 | 302 | 182 | ||
cambio real | 12% | 20% | 10% | 18% | (10%) | ||
Cambio de CER | 15% | 20% | 17% | 15% | (2%) |
Región | Conductores y comentarios | |
TODO EL MUNDO | * Strong global demand for Tagrisso in adjuvant (ADAURA) and 1st -line setting (FLAURA) | |
US | * Continued strong adjuvant and 1st-line demand growth | |
Mercados Emergentes | * Encouraging demand growth across markets with some positive impact of hospital ordering dynamics in China * Strong performance across Latin America and Asia Pacific markets | |
Europa | * Continued growth in 1st-line setting and increasing adjuvant demand | |
DdV establecido | * Increased demand in adjuvant and 1st-line offset by a 10.5% mandatory price reduction in Japan effective June 2023 |
Imfinzi
Los ingresos totales | TODO EL MUNDO | US | Mercados Emergentes | Europa | DdV establecido | ||
Q1 2024 $m | 1,113 | 582 | 129 | 232 | 170 | ||
cambio real | 29% | 19% | 59% | 43% | 31% | ||
Cambio de CER | 33% | 19% | 83% | 40% | 45% |
Región | Conductores y comentarios | |
TODO EL MUNDO | * Continued growth driven by BTC (TOPAZ-1), HCC (HIMALAYA), and increased patient share in Stage IV NSCLC (POSEIDON) and extensive-stage SCLC (CASPIAN) | |
US | * Continued demand growth driven by BTC, HCC, and extensive-stage SCLC * Growth in BTC slowing with Imfinzi now the clear standard-of-care | |
Mercados Emergentes | * Continued China growth driven by demand in HCC | |
Europa | * Growth driven by share gains in extensive-stage SCLC and new indications | |
DdV establecido | * Increased demand from new launches, offset by a 25% mandatory price reduction in Japan effective 1 February 2024 |
lynparza
Los ingresos totales | TODO EL MUNDO | US | Mercados Emergentes | Europa | DdV establecido | ||
Q1 2024 $m | 705 | 288 | 167 | 191 | 59 | ||
cambio real | 8% | 7% | 23% | 7% | (13%) | ||
Cambio de CER | 11% | 7% | 33% | 5% | (6%) |
Región | Conductores y comentarios | |
TODO EL MUNDO | * lynparza remains the leading medicine in the PARP inhibitor class globally across four tumour types (ovarian, breast, prostate, pancreatic), as measured by total prescription volume * No Collaboration Revenue for lynparza was recognised in either Q1 2024 or Q1 2023, hence the Product Sales numbers are identical to the Total Revenue numbers shown above | |
US | * Continued leadership within PARPi class despite increasing competition, negative class pressure and maturity of the market | |
Mercados Emergentes | * Demand growth in China coming from newly diagnosed BRCA-mutated ovarian cancer (SOLO-1) and inclusion of HRD-positive ovarian cancer (PAOLA-1) on NRDL with no price reduction | |
Europa | * Demand growth driven by mCRPC (PROpel) and early breast cancer (OlympiA) | |
DdV establecido | * Demand growth coming from HRD-positive ovarian cancer, partially offset by price reduction in Japan effective from November 2023 |
Enhertu
Los ingresos totales | TODO EL MUNDO | US | Mercados Emergentes | Europa | DdV establecido | ||
Q1 2024 $m | 461 | 202 | 112 | 134 | 13 | ||
cambio real | 79% | 26% | > 2x | > 2x | > 3x | ||
Cambio de CER | 79% | 26% | > 2x | > 2x | > 3x |
Región | Conductores y comentarios | |
TODO EL MUNDO | * ventas combinadas de Enhertu, recorded by Daiichi Sankyo and AstraZeneca, amounted to $879m in Q1 2024 (Q1 2023: $531m) | |
US | * US in-market sales, recorded by Daiichi Sankyo, amounted to $423m in Q1 2024 (Q1 2023: $336m) * Strong demand across launched indications | |
Mercados Emergentes | * Strong uptake in China following HER2-positive (DESTINY-Breast03) and HER2-low (DESTINY-Breast04) launches * Some launch-related inventory build was observed in China in Q1 2024 | |
Europa | * Crecimiento continuo impulsado por una mayor adopción en el cáncer de mama metastásico HER2 positivo y HER2 bajo | |
DdV establecido | * AstraZeneca's Alliance Revenue includes a mid single-digit percentage royalty on Daiichi Sankyo's sales in Japan |
Calcuencia
Los ingresos totales | TODO EL MUNDO | US | Mercados Emergentes | Europa | DdV establecido | ||
Q1 2024 $m | 718 | 494 | 39 | 153 | 32 | ||
cambio real | 35% | 29% | > 2x | 42% | 44% | ||
Cambio de CER | 35% | 29% | > 2x | 39% | 47% |
Región | Conductores y comentarios | |
TODO EL MUNDO | * Sustained leadership in front-line CLL with increased global penetration | |
US | * Continued market growth and maintaining leading share of new CLL patient starts in the front line | |
Europa | * Continued growth supported by launches in further European markets |
Otros medicamentos oncológicos
Q1 2024 | Cambios |
Los ingresos totales | $m | Real | CER | Conductores y comentarios | |
Zoladex | 285 | 21% | 28% | * Strong underlying growth in China and Emerging Markets and moderate growth in Europe offset by drop in Japan | |
Imjudo | 62 | 66% | 70% | * Continued growth across markets slightly offset by US inventory destocking in Q1 2024 | |
Truqap | 50 | Nuevo Méjico | Nuevo Méjico | * Rapid adoption following US approval in November 2023 for HR-positive HER2-negative metastatic breast cancer with one or more biomarker alterations (CAPItello-291) * Some benefit from later-line use | |
Orpatías | 12 | 43% | 49% | * Demand in in China for the treatment of patients with NSCLC with MET exon 14 skipping alterations | |
Otra oncología | 107 | (24%) | (19%) | * Decline in use of Iressa en China |
Biofarmacéuticos
BioPharmaceuticals Total Revenue increased by 14% (16% at CER) in Q1 2024 to $5,178m, representing 41% of overall Total Revenue (Q1 2023: 42%).
Productos biofarmacéuticos - CVRM
CVRM Total Revenue increased by 20% (23% at CER) to $3,060m in Q1 2024 and represented 24% of overall Total Revenue (Q1 2023: 24%).
Farxiga
Los ingresos totales | TODO EL MUNDO | US | Mercados Emergentes | Europa | DdV establecido | ||
Q1 2024 $m | 1,892 | 475 | 711 | 553 | 152 | ||
cambio real | 43% | 61% | 43% | 41% | 10% | ||
Cambio de CER | 45% | 61% | 50% | 37% | 18% |
Región | Conductores y comentarios | |
TODO EL MUNDO | * Farxiga volume is growing faster than the overall SGLT2 market in most major regions, fuelled by launches in heart failure and CKD, and also the launch of an authorised generic in the US. SGLT2 class growth underpinned by updated cardiorenal guidelines | |
US | * Growth driven by heart failure and CKD * Sales in the quarter benefitted from the introduction of an authorised generic | |
Mercados Emergentes
| * Solid growth despite entry of generic competition in some markets * Strong momentum in Latin America * Sales in the quarter benefited from the timing of government tenders | |
Europa | * Continued strong class growth and market share gains fuelled by HFpEF approval in 2023 and guidelines updates | |
DdV establecido | * In Japan, a milestone payment of $45m was received in the quarter from AstraZeneca's partner Ono Pharmaceutical Co., Ltd, which records in-market sales |
Brilinta
Los ingresos totales | TODO EL MUNDO | US | Mercados Emergentes | Europa | DdV establecido | ||
Q1 2024 $m | 323 | 163 | 88 | 67 | 5 | ||
cambio real | (3%) | (9%) | 8% | (1%) | (12%) | ||
Cambio de CER | (1%) | (9%) | 21% | (3%) | (14%) |
Región | Conductores y comentarios | |
US | * Stable volume but unfavourable gross-to-net adjustments in the quarter | |
Mercados Emergentes | * Growth despite generics pressure in some markets | |
Europa | * Declining volume | |
DdV establecido | * Caída de ventas impulsada por la entrada de genéricos en Canadá |
Otros medicamentos CVRM
Q1 2024 | Cambios |
Los ingresos totales | $m | Real | CER | Conductores y comentarios | |
Crestor | 297 | (3%) | 2% | * Continued sales growth in Emerging Markets | |
seloken | 165 | (8%) | (2%) | * Impacto continuo de la implementación del VBP en China | |
Lokelma | 114 | 16% | 19% | * Continued launches in new markets | |
roxadustato
Andexxa | 77
47 | 24%
6% | 28%
6% | * Increased demand in both the dialysis and non-dialysis-dependent populations. NRDL listing renewed * Growth driven by Europe | |
Wainua | 5 | Nuevo Méjico | Nuevo Méjico | * Approved for ATTRv-PN in the US in December 2023 | |
Otros CVRM | 141 | (33%) | (31%) |
Biofarmacéuticos - I+i
Total Revenue of $1,886m from R&I medicines increased 15% (17% at CER) and represented 15% of overall Total Revenue (Q1 2023: 15%). This reflected growth in fasenra, Tezspire, Breztri, saphnelo y Airsupra tras su reciente lanzamiento.
fasenra
Los ingresos totales | TODO EL MUNDO | US | Mercados Emergentes | Europa | DdV establecido | ||
Q1 2024 $m | 358 | 210 | 22 | 93 | 33 | ||
cambio real | 6% | 5% | 56% | 6% | (6%) | ||
Cambio de CER | 6% | 4% | 61% | 4% | - |
Región | Conductores y comentarios | |
TODO EL MUNDO | * Continued asthma market share leadership in IL-5 class across major markets | |
US | * Maintained share of a growing market | |
Mercados Emergentes | * Continued strong demand growth driven by launch acceleration across key markets | |
Europa | * Expanded leadership in severe eosinophilic asthma | |
DdV establecido | * In Japan, maintained class leadership in a broadly stable market |
Breztri
Los ingresos totales | TODO EL MUNDO | US | Mercados Emergentes | Europa | DdV establecido | ||
Q1 2024 $m | 219 | 105 | 70 | 30 | 14 | ||
cambio real | 52% | 30% | 83% | 97% | 43% | ||
Cambio de CER | 54% | 30% | 91% | 93% | 53% |
Región | Conductores y comentarios | |
TODO EL MUNDO | * Fastest growing medicine within the expanding FDC triple class, across major markets | |
US | * Crecimiento constante de la participación dentro de la clase triple de FDC en productos nuevos y el mercado total | |
Mercados Emergentes | * Liderazgo mantenido en participación de mercado en China con una fuerte penetración de clase triple FDC * Further expansion with launches in additional geographies | |
Europa | * Crecimiento sostenido en todos los mercados a medida que continúan avanzando los nuevos lanzamientos | |
DdV establecido | * Increased market share within the COPD indication in Japan and strong launch in Canada |
Tezspire
Los ingresos totales | TODO EL MUNDO | US | Mercados Emergentes | Europa | DdV establecido | ||
Q1 2024 $m | 120 |
| 77 | 2 | 27 | 14 | |
cambio real | > 2x |
| 80% | Nuevo Méjico | > 4x | > 3x | |
Cambio de CER | > 2x |
| 80% | Nuevo Méjico | > 3x | > 3x |
Región | Conductores y comentarios | |
TODO EL MUNDO | * ventas combinadas de Tezspire, recorded by Amgen and AstraZeneca, amounted to $216m in Q1 2024 (Q1 2023: $105m) | |
US | * Continued growth in total prescriptions, and maintained new-to-brand market share with majority of patients new to biologics | |
Europa | * Achieved new-to-brand leadership across multiple markets, new launches continue to progress | |
DdV establecido | * Japón mantuvo el liderazgo en novedades de marca |
SYMBICORT®
Los ingresos totales | TODO EL MUNDO | US | Mercados Emergentes | Europa | DdV establecido | ||
Q1 2024 $m | 769 | 299 | 253 | 142 | 75 | ||
cambio real | 12% | 28% | 11% | (3%) | (5%) | ||
Cambio de CER | 14% | 28% | 18% | (6%) | (3%) |
Región | Conductores y comentarios | |
TODO EL MUNDO | * SYMBICORT® remained the global market leader within a stable ICS/LABA class | |
US | * Encouraging demand following list price reduction | |
Mercados Emergentes | * Strong underlying demand for SYMBICORT® in both China and Ex-China Emerging Markets, strengthened position as market leader in the region | |
Europa | * Continua erosión de precios y volúmenes debido a los genéricos y desaceleración del mercado general | |
DdV establecido | * Continued generic erosion in Japan |
Otros medicamentos de I+D
Q1 2024 | Cambios |
Los ingresos totales | $m | Real | CER | Conductores y comentarios | |
Pulmicort |
| 224 | 1% | 5% | * >80% of revenues from Emerging Markets |
saphnelo |
| 91 | 94% | 95% | * Demand acceleration in the US, and additional growth driven by ongoing launches in Europe and Established RoW |
Airsupra |
| 7 | Nuevo Méjico | Nuevo Méjico | * Strong launch momentum with increase class penetration and volume uptake. Revenue in the quarter reflects introductory discounts as early access continues to build |
Otros I+D | 98 | (30%) | (29%) | * Competencia genérica |
Biofarmacéuticos - V&I
Total Revenue from V&I medicines reduced by 35% (34% at CER) to $232m (Q1 2023: $355m) and represented 2% of overall Total Revenue (Q1 2023: 3%), principally due to a decline in sales of COVID-19 mAbs.
V&I medicines
Q1 2024 | Cambios |
Los ingresos totales | $m | Real | CER | Conductores y comentarios | |
beyfortus |
| 46 | Nuevo Méjico | Nuevo Méjico | * Product Sales recognises AstraZeneca's sales of manufactured beyfortus product to Sanofi * Alliance Revenue recognises AstraZeneca's 50% share of gross profits on sales of beyfortus in major markets outside the US, and 25% of brand revenues in rest of world markets * AstraZeneca has no participation in US profits or losses |
Synagis |
| 171 | (13%) | (13%) | * Disminución en Synagis more than offset by growth in beyfortus |
mAb de COVID-19 | 2 | (99%) | (99%) | * Disminución en evushelado sales (Q1 2023: $127m) | |
FluMist | 7 | > 2x | > 2x | * Normal seasonality | |
Other V&I | 6 | (79%) | (80%) | * Disminución en Vaxzevria sales (Q1 2023: $28m) |
Enfermedad rara
Total Revenue from Rare Disease medicines increased by 12% (16% at CER) in Q1 2024 to $2,096m, representing 17% of overall Total Revenue (Q1 2023: 17%).
Ultomiris
Los ingresos totales | TODO EL MUNDO | US | Mercados Emergentes | Europa | DdV establecido | ||
Q1 2024 $m | 859 | 482 | 32 | 202 | 143 | ||
cambio real | 32% | 27% | > 2x | 27% | 46% | ||
Cambio de CER | 34% | 27% | > 2x | 24% | 61% |
Región | Conductores y comentarios | |
TODO EL MUNDO | * Growth across neurology, geographic expansion, patient demand and Soliris conversión * Se puede esperar una variabilidad intertrimestral en el crecimiento de los ingresos debido a Ultomiris every eight-week dosing schedule and lower average annual treatment cost compared to Soliris | |
US | * Growth in naïve patients in gMG and conversion from Soliris a través de indicaciones compartidas | |
Mercados Emergentes | * Continued growth following launches in new markets | |
Europa | * Fuerte generación de demanda tras los lanzamientos en nuevos mercados, particularmente en indicaciones de neurología, así como la conversión acelerada de Soliris in key markets, partially offset by price reductions to secure reimbursement for new indications | |
DdV establecido | * Conversión continua de Soliris y fuerte demanda tras nuevos lanzamientos |
Soliris
Los ingresos totales | TODO EL MUNDO | US | Mercados Emergentes | Europa | DdV establecido | ||
Q1 2024 $m | 739 | 411 | 125 | 142 | 61 | ||
cambio real | (11%) | (8%) | 9% | (23%) | (30%) | ||
Cambio de CER | (8%) | (8%) | 37% | (24%) | (28%) |
Región | Conductores y comentarios | |
US | * Disminución impulsada por la conversión exitosa de Soliris pacientes a Ultomiris en HPN, SHUa y gMG, parcialmente compensado por Soliris crecimiento en NMOSD | |
Mercados Emergentes | * Growth driven by patient demand following launches in new markets | |
Europa | * Disminución impulsada por la conversión exitosa de Soliris a Ultomiris as well as biosimilar erosion in PNH and aHUS | |
DdV establecido | * Disminución impulsada por la conversión exitosa de Soliris a Ultomiris |
Strensiq
Los ingresos totales | TODO EL MUNDO | US | Mercados Emergentes | Europa | DdV establecido | ||
Q1 2024 $m | 313 | 246 | 21 | 24 | 22 | ||
cambio real | 20% | 20% | 44% | 15% | 4% | ||
Cambio de CER | 21% | 20% | 67% | 12% | 14% |
Región | Conductores y comentarios | |
TODO EL MUNDO | * Growth driven by strong patient demand |
Otros medicamentos para enfermedades raras
Q1 2024 | Cambios |
Los ingresos totales | $m | Real | CER | Conductores y comentarios | |
Koselugo | 132 | 68% | 82% | * Driven by patient demand and expansion in new markets. The quarter benefitted from tender market order timing in Emerging Markets | |
Kanuma | 53 | 32% | 35% | * Continued global demand |
Otros medicamentos (fuera de las principales áreas terapéuticas)
Q1 2024 | Cambios |
Los ingresos totales | $m | Real | CER | Conductores y comentarios | |
Nexium |
| 243 | (2%) | 7% | * Growth in Emerging Markets offset declines elsewhere |
Otros | 54 | (25%) | (23%) | * Continued impact of generic competition |
Rendimiento financiero
Mesa 9: Pérdidas y ganancias informadas
Q1 2024 | Q1 2023 | % Cambio |
|
| $m | $m | Real | CER |
Los ingresos totales |
| 12,679 | 10,879 | 17 | 19 |
- Venta de productos | 12,177 | 10,566 | 15 | 18 | |
- Ingresos de la Alianza | 457 | 286 | 59 | 59 | |
- Ingresos por colaboración | 45 | 27 | 66 | 66 | |
El costo de ventas | (2,218) | (1,905) | 16 | 18 | |
Beneficio bruto |
| 10,461 | 8,974 | 17 | 20 |
Gasto de distribución | (135) | (134) | 1 | 3 | |
Gastos de I + D | (2,783) | (2,611) | 7 | 7 | |
gastos de venta, generales y administrativos | (4,495) | (4,059) | 11 | 12 | |
Otros ingresos y gastos operativos | 67 | 379 | (83) | (83) | |
Beneficio operativo | 3,115 | 2,549 | 22 | 31 | |
Gastos financieros netos | (302) | (287) | 5 | 1 | |
Empresas conjuntas y asociadas | (13) | - | Nuevo Méjico | Nuevo Méjico | |
Beneficio antes de impuestos |
| 2,800 | 2,262 | 24 | 34 |
Taxation | (620) | (458) | 35 | 46 | |
Tasa de impuesto |
| 22% | 20% |
| |
Beneficio después de impuestos |
| 2,180 | 1,804 | 21 | 30 |
Ganancias por acción |
| $1.41 | $1.16 | 21 | 30 |
Mesa 10: Conciliación de la utilidad reportada antes de impuestos con el EBITDA
Q1 2024 | Q1 2023 | % Cambio |
$m | $m | Real | CER | ||
Beneficio declarado antes de impuestos | 2,800 | 2,262 | 24 | 34 | |
Gastos financieros netos | 302 | 287 | 5 | 1 | |
Empresas conjuntas y asociadas | 13 | - | Nuevo Méjico | Nuevo Méjico | |
Depreciación, amortización y deterioro | 1,255 | 1,502 | (16) | (17) | |
Comparable | 4,370 | 4,051 | 8 | 13 |
Mesa 11: Conciliación de las medidas financieras reportadas con las principales: segundo trimestre de 1[ 7 ]
Q1 2024 | reportado | Reestructuración | Amortización y deterioro de activos intangibles | Otro | Core | Core % Cambio |
$m | $m | $m | $m | $m | Real | CER | ||
Beneficio bruto |
| 10,461 | 20 | 10 | - | 10,491 | 15 | 18 |
Margen bruto de ventas de productos |
| 82% |
|
|
| 82% | -1pp | -1pp |
Gasto de distribución | (135) | - | - | - | (135) | 1 | 3 | |
Gastos de I + D | (2,783) | 80 | 4 | 1 | (2,698) | 17 | 18 | |
% de ingresos totales | 22% | 21% | - | - | ||||
gastos de venta, generales y administrativos | (4,495) | 97 | 941 | 44 | (3,413) | 12 | 13 | |
% de ingresos totales | 35% | 27% | + 1pp | + 1pp | ||||
Gastos operativos totales | (7,413) | 177 | 945 | 45 | (6,246) | 14 | 15 | |
Otros ingresos y gastos operativos | 67 | (2) | - | - | 65 | (80) | (80) | |
Beneficio operativo |
| 3,115 | 195 | 955 | 45 | 4,310 | 9 | 15 |
Margen operativo |
| 25% |
|
|
| 34% | -2pp | -1pp |
Gastos financieros netos | (302) | - | - | 57 | (245) | 2 | (3) | |
Taxation | (620) | (45) | (183) | (19) | (867) | 19 | 25 | |
EPS |
| $1.41 | $0.10 | $0.50 | $0.05 | $2.06 | 7 | 13 |
Controladores de pérdidas y ganancias
Beneficio bruto
- The calculation of Reported and Core Product Sales Gross Margin excludes the impact of Alliance Revenue and Collaboration Revenue
- The change in Product Sales Gross Margin (Reported and Core) in Q1 2024 was impacted by:
- Positive effects from product mix. The increased contribution from Rare Disease and Oncology medicines had a positive impact on the Product Sales Gross Margin
- Efectos diluyentes de la mezcla de productos. La creciente contribución de las ventas de productos con acuerdos de participación en los beneficios (Lynparza, Enhertu, Tezspire, Koselugo) has a negative impact on Product Sales Gross Margin because AstraZeneca records Product Sales in certain markets and pays away a share of the gross profits to its collaboration partners. The growth in beyfortus also has a dilutive impact on Product Sales Gross Margin, as AstraZeneca is responsible for manufacturing, and Sanofi is responsible for distribution. AstraZeneca records its sales to Sanofi as Product Sales, which generate a lower Product Sales Gross Margin than the Company average
- Dilutive effects from geographic mix. In Emerging Markets, the Product Sales Gross Margin tends to be below the Company average
- Variations in Product Sales Gross Margin performance between periods can continue to be expected due to product seasonality, foreign exchange fluctuations, and other effects
Gastos de I + D
- La variación del gasto en I+D (Reportado y Core) en el periodo se vio impactada por:
- Lecturas de datos positivos recientes para varios medicamentos de alta prioridad que han cerrado ensayos en etapa avanzada
- Inversión en plataformas, nuevas tecnologías y capacidades para mejorar la productividad en I+D
- The change in Reported R&D expense was also impacted by intangible asset impairments in the prior period
gastos de venta, generales y administrativos
- El cambio en los gastos de venta, generales y administrativos (reportados y básicos) en el período fue impulsado principalmente por actividades de desarrollo de mercado para lanzamientos.
Otros ingresos y gastos operativos
- In the prior year period, Other operating income and expense included a $241m gain on the disposal of the US rights to Pulmicort flexhaler
Gastos financieros netos
- Core Net finance expense increased 2% (3% decrease at CER) with higher rates on floating debt and bond issuances broadly offset by higher interest received on cash and short-term investments
Taxation
- The effective Reported Tax rate for the three months to 31 March 2024 was 22% (Q1 2023: 20%) and the effective Core Tax rate was 21% (Q1 2023: 20%)
- The cash tax paid for the three months to 31 March 2024 was $430m (Q1 2023: $225m), representing 15% of Reported Profit before tax (Q1 2023: 10%)
Mesa 12: Resumen de flujo de caja
Q1 2024 | Q1 2023 | Cambios | ||
$m | $m | $m | ||
Beneficio operativo informado | 3,115 | 2,549 | 566 | |
Depreciación, amortización y deterioro | 1,255 | 1,502 | (247) | |
Movement in working capital and short-term provisions | (455) | 242 | (697) | |
Ganancias por enajenación de activos intangibles | - | (249) | 249 | |
Movimientos del valor razonable sobre contraprestaciones contingentes que surgen de combinación de negocios | 16 | - | 16 | |
Movimientos no monetarios y otros | (674) | (429) | (245) | |
Pago interesado | (341) | (257) | (84) | |
Impuestos pagados | (430) | (225) | (205) | |
Entrada neta de efectivo de las actividades operativas | 2,486 | 3,133 | (647) | |
Entrada neta de efectivo antes de actividades de financiación | 73 | 1,887 | (1,814) | |
Entradas / (salidas) netas de efectivo de actividades de financiación | 2,028 | (2,031) | 4,059 |
The change in Net cash inflow before financing activities in the quarter to 31 March 2024 is primarily driven by the movement in Acquisitions of subsidiaries, net of cash acquired, of $537m, and relates to the acquisition of Gracell Biotechnologies, Inc. for $726m compared to the acquisition of Neogene Therapeutics, Inc. for $189m in Q1 2023.
The change in Net cash inflow/(outflow) from financing activities of $4,059m is primarily driven by the increase in Issue of loans and borrowings of $1,150m, and by the decrease in Repayment of loans and borrowings of $1,997m.
Gastos de capital
Capital expenditure amounted to $417m in the three months to 31 March 2024 (Q1 2023: $247m). Capital expenditure is expected to increase substantially in 2024, driven by investment in several major manufacturing projects and continued investment in technology upgrades.
Mesa 13: Resumen de deuda neta
a los 31 Marzo 2024 | a los 31 Diciembre 2023 | a los 31 Mar. De 2023 | |
$m | $m | $m | |
Efectivo y equivalentes de efectivo | 7,841 | 5,840 | 6,232 |
Otras inversiones | 180 | 122 | 230 |
Efectivo e inversiones | 8,021 | 5,962 | 6,462 |
Sobregiros y empréstitos a corto plazo | (477) | (515) | (593) |
Papel comercial | (980) | - | (74) |
Pasivos por arrendamiento | (1,242) | (1,128) | (962) |
Cuotas vigentes de préstamos | (4,593) | (4,614) | (2,958) |
Cuotas no corrientes de préstamos | (27,259) | (22,365) | (26,916) |
Préstamos y empréstitos que devengan intereses (Deuda bruta) | (34,551) | (28,622) | (31,503) |
Derivados netos | 81 | 150 | (21) |
Deuda neta | (26,449) | (22,510) | (25,062) |
Net debt increased by $3,939m in the three months to 31 March 2024 to $26,449m. Details of the committed undrawn bank facilities are disclosed within the going concern section of Note 1. Details of the Company's solicited credit ratings and further details on Net debt are disclosed in Note 3.
Asignacion de capital
El objetivo del Consejo es continuar logrando un equilibrio entre los intereses del negocio, los acreedores financieros y los accionistas de la Compañía. Las prioridades de asignación de capital de la Compañía incluyen: invertir en el negocio y en el oleoducto; mantener una calificación crediticia sólida y de grado de inversión; posibles oportunidades de desarrollo empresarial que mejoren el valor; y apoyar la política progresiva de dividendos.
Al aprobar la declaración de dividendos, el Directorio considera tanto la liquidez de la empresa como el nivel de reservas legalmente disponibles para su distribución. Los dividendos se pagan a los accionistas de AstraZeneca PLC, una sociedad de cartera del Grupo sin operaciones directas. La capacidad de AstraZeneca PLC para realizar distribuciones a los accionistas depende de la creación de ganancias para la distribución y la recepción de fondos de las empresas subsidiarias. Las reservas consolidadas del Grupo establecidas en el estado de situación financiera consolidado resumido no reflejan la utilidad disponible para distribución a los accionistas de AstraZeneca PLC.
Información financiera resumida para garantía de valores de subsidiarias
AstraZeneca Finance LLC ("AstraZeneca Finance") is the issuer of 0.7% Notes due 2024, 1.2% Notes due 2026, 4.8% Notes due 2027, 4.875% Notes due 2028, 1.75% Notes due 2028, 4.85% Notes due 2029, 4.9% Notes due 2030, 4.9% Notes due 2031, 2.25% Notes due 2031, 4.875% Notes due 2033 and 5% Notes due 2034 (the "AstraZeneca Finance Notes"). Each series of AstraZeneca Finance Notes has been fully and unconditionally guaranteed by AstraZeneca PLC. AstraZeneca Finance is 100% owned by AstraZeneca PLC and each of the guarantees issued by AstraZeneca PLC is full and unconditional and joint and several.
Las Obligaciones Negociables de AstraZeneca Finance son obligaciones senior no garantizadas de AstraZeneca Finance y tienen el mismo rango que todas las deudas senior no garantizadas y no subordinadas existentes y futuras de AstraZeneca Finance. La garantía de AstraZeneca PLC de los pagarés financieros de AstraZeneca es la obligación senior no garantizada de AstraZeneca PLC y se ubica a la par con todas las deudas senior no garantizadas y no subordinadas existentes y futuras de AstraZeneca PLC. Cada garantía de AstraZeneca PLC está efectivamente subordinada a cualquier deuda garantizada de AstraZeneca PLC en la medida del valor de los activos que garantizan dicha deuda. Las Obligaciones Negociables de AstraZeneca están estructuralmente subordinadas al endeudamiento y otros pasivos de las subsidiarias de AstraZeneca PLC, ninguna de las cuales garantiza las Obligaciones Negociables de AstraZeneca.
AstraZeneca PLC administra sustancialmente todas sus operaciones a través de divisiones, sucursales y / o inversiones en subsidiarias y afiliadas. En consecuencia, la capacidad de AstraZeneca PLC para pagar su deuda y garantizar obligaciones también depende de las ganancias de sus subsidiarias, afiliadas, sucursales y divisiones, ya sea por dividendos, distribuciones, préstamos u otros.
Please refer to the Consolidated financial statements of AstraZeneca PLC in our Annual Report on Form 20‑F and reports on Form 6-K with our quarterly financial results as filed or furnished with the SEC for further financial information regarding AstraZeneca PLC and its consolidated subsidiaries. For further details, terms and conditions of the AstraZeneca Finance Notes please refer to AstraZeneca PLC's reports on Form 6-K furnished to the SEC on 22 February 2024, 3 March 2023 and 28 May 2021.
De conformidad con la Regla 13-01 y la Regla 3-10 de la Regulación SX bajo la Ley de Valores de 1933, según enmendada (la "Ley de Valores"), presentamos a continuación la información financiera resumida de AstraZeneca PLC, como Garante, excluyendo sus subsidiarias consolidadas, y AstraZeneca Finance, como emisor, excluyendo sus subsidiarias consolidadas. La siguiente información financiera resumida de AstraZeneca PLC y AstraZeneca Finance se presenta en forma combinada y las transacciones entre las entidades que se combinan han sido eliminadas. Se excluye la información financiera para entidades no garantes. Los saldos y transacciones intercompañías entre el grupo deudor y las subsidiarias no obligatorias se presentan en líneas separadas.
Mesa 14: Grupo deudor resumido Estado de resultados integrales
| Q1 2024 | Q1 2023 | |
| $m | $m | |
Los ingresos totales | - | - | |
Beneficio bruto | - | - | |
Pérdida operativa | - | - | |
Pérdida del período | (234) | (237) | |
Transacciones con subsidiarias que no son emisoras ni garantes | 588 | 7,502 |
Mesa 15: Grupo deudor resumido Estado de situación financiera
| A 31 de marzo de 2024 | A 31 de marzo de 2023 | |
| $m | $m | |
Activos circulantes | 12 | 10 | |
Activos no corrientes | - | - | |
Pasivo circulante | (5,778) | (2,952) | |
Pasivos no corrientes | (27,161) | (26,747) | |
Cantidades adeudadas por subsidiarias que no son emisoras ni garantes | 21,242 | 14,067 | |
Cantidades adeudadas a subsidiarias que no son emisoras ni garantes | - | (296) |
Divisas
The Company's transactional currency exposures on working capital balances, which typically extend for up to three months, are hedged where practicable using forward foreign exchange contracts against the individual companies' reporting currency. Foreign exchange gains and losses on forward contracts transacted for transactional hedging are taken to profit or to Other comprehensive income if the contract is in a designated cashflow hedge. In addition, the Company's external dividend payments, paid principally in pound sterling and Swedish krona, are fully hedged from announcement to payment date.
Mesa 16: sensibilidades de moneda
The Company provides the following information on currency-sensitivity:
| Normal tasas frente a USD | Impacto anual ($m) del fortalecimiento del 5% (FY 2024 average rate vs. FY 2023 average) [ 8 ] | ||||||||||
Moneda | Relevancia primaria |
| FY | el último año | Cambios (%) | Marzo 2024[ 11 ] | Cambios (%) |
| Los ingresos totales | Beneficio operativo básico | ||
EUR | Los ingresos totales | 0.92 | 0.92 | 0 | 0.92 | 0 | 397 | 179 | ||||
CNY | Los ingresos totales | 7.09 | 7.20 | (2) | 7.22 | (2) | 322 | 182 | ||||
JPY | Los ingresos totales | 140.60 | 148.49 | (5) | 149.87 | (6) | 177 | 119 | ||||
Otro[ 12 ] | 453 | 227 | ||||||||||
GBP | Gastos de operacion | 0.80 | 0.79 | 2 | 0.79 | 2 | 60 | (126) | ||||
SEK | Gastos de operacion | 10.61 | 10.39 | 2 | 10.41 | 2 | 9 | (63) | ||||
Sostenibilidad
AstraZeneca published its tenth annual Reporte de Sostenibilidad, including a data annex for performance measures and targets, along with the 2023 Taskforce on Climate-related Financial Disclosures Statement.
Acceso a la asistencia sanitaria
- Chair Michel Demaré participated in a panel discussion with global health leaders at the 54th Annual Meeting of the World Economic Forum (WEF) in Davos on utilising learnings from the COVID-19 pandemic to prepare for future health challenges and the importance of investing in strong, resilient health systems.
- Engagements linked to the Asociación para la sostenibilidad y resiliencia del sistema de salud (PHSSR), continued in Germany, Belgium, Switzerland and Japan, highlighting the need for measurable policy targets for non-communicable disease management. In India, a PHSSR report was published assessing the sustainability and resilience of the Indian health system, while in the Netherlands, an academic publication was launched with policy recommendations to improve health system resilience.
- Healthy Heart Africa (HHA), AstraZeneca's flagship health equity programme, reached its goal of identifying more than 10 million people with elevated blood pressure by 2025 nearly two years ahead of target. At the end of February 2024, more than 11,480 healthcare workers have been trained and more than 52 million blood pressure screenings conducted cumulatively since the programme launched in 2014, maintaining an average of more than one million screenings per month since 2023. HHA also launched a pilot programme in Ghana in March 2024 as a first step to broadening its scope to include chronic kidney disease screening.
- Since 2021, the Young Health Programme (YHP) has directly reached more than 10 million youth, influenced 16 policies and has employee volunteer programmes in 36 countries, exceeding its core targets for 2021-2025 nearly two years early. YHP received the Driving Health Equity Award in the 2024 Reuters Pharma Awards Europe for the programme's work empowering young people to catalyse a healthier future.
Protección ambiental
- The Company signed a clean heat agreement in March 2024 to decarbonise our medicines manufacturing in China. Through the agreement, biomethane and biomethane-based steam will be supplied to our Wuxi manufacturing site and we will reduce our Scope 1 and 2 greenhouse gas (GHG) emissions by up to 80% in China, supporting the broader decarbonisation of the healthcare system.
- La Compañía announced at WEF that it will be one of the inaugural Early Adopter organisations that intend to start making disclosures aligned with the Grupo de trabajo sobre divulgaciones financieras relacionadas con la naturaleza (TNFD) Recommendations in corporate reporting by the fiscal year 2024.
- AstraZeneca was one of the five healthcare companies, convened through the Sustainable Markets Initiative Health Systems Task Force, that launched an industry-first multi-party agreement to access renewable power in China in January 2024. This is the first time companies from across the global healthcare sector have come together to decarbonise their operations in China, and the agreement will result in potential annual emissions savings of approximately 120,000 tonnes of carbon dioxide equivalent (CO2e).
- AstraZeneca received the Sustainability Award in the 2024 Reuters Pharma Awards Europe for accelerating the electronic product information industry transition in Europe.
Ética y transparencia
- The Company achieved seventh place overall, and third in the Health Care sector, in the FTSE Women Leaders Review 2023, as one of the top performers in both the FTSE 100 and FTSE 350 for representation of women across the organisation.
- The Company's latest Modern Slavery Act Statement was published detailing activities undertaken to mitigate the risks of modern slavery both within the Company's operations and supply chain, in line with the Code of Ethics and our commitment to operating with integrity and in compliance with relevant legislation.
- In Poland, AstraZeneca was named an 'Ethics Leader' by Bonnier Press for the third year. This award recognises five companies for their commitment to upholding high ethical standards, treating business partners with respect, applying the principles of fair competition, and building trust and good relationships between employees and stakeholder groups.
Investigación y desarrollo
This section covers R&D events and milestones that have occurred since the prior results announcement on 8 February 2024, up to and including events on 24 April 2024.
Puede encontrar una visión completa de la cartera de medicamentos de AstraZeneca en ensayos en humanos en el último Apéndice de ensayos clínicos, disponible en www.astrazeneca.com/relaciones-con-inversionistas. El Apéndice de Ensayos Clínicos incluye tablas con detalles de los ensayos clínicos en curso para los medicamentos de AstraZeneca y las nuevas entidades moleculares en proceso.
Oncología
AstraZeneca presented new data across its diverse portfolio of cancer medicines at four major medical congresses since the prior results announcement: the Society of Gynecologic Oncology Annual Meeting on Women's Cancer (SGO) in March 2024, the European Lung Cancer Congress (ELCC) in March 2024, American Association for Cancer Research Annual Meeting (AACR) in April 2024 and the 2024 Cholangiocarcinoma Foundation Conference (CFC) in April 2024.
Tagrisso
Evento | Comentario | ||
Phase III trial read out | LAURA | Se cumplió el criterio de valoración principal, lo que demuestra que Tagrisso resulted in a statistically significant and highly clinically meaningful improvement in PFS for patients with unresectable, Stage III EGFRm NSCLC after chemoradiotherapy compared to placebo after chemoradiotherapy. (February 2024) | |
Aprobación | US | Tagrisso with the addition of chemotherapy for the treatment of adult patients with locally advanced or metastatic EGFRm NSCLC. (FLAURA2, February 2024) | |
Presentation: ELCC | FLAURA2 | OS interim analysis of the Phase III FLAURA2 trial, presented at ELCC, showed at 41% data maturity, a favourable trend with the Tagrisso plus chemotherapy arm (HR 0.75) vs Tagrisso monotherapy. The OS data were not statistically significant at this interim analysis and will continue to be assessed as a key secondary endpoint at final analysis. (March 2024) |
Imfinzi y Imjudo
Evento | Comentario | ||
Phase III trial read out | ADRIÁTICO
|
| Se cumplió el criterio de valoración principal, lo que demuestra que Imfinzi resulted in a statistically significant and clinically meaningful improvement in the dual primary endpoints of OS and PFS in patients with LS-SCLC who had not progressed following cCRT compared to placebo after cCRT. (April 2024). |
Presentation: CFC | TOPACIO-1 |
| Updated exploratory results of the Phase III TOPAZ-1 trial, presented at CFC, showed Imfinzi in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term OS benefit at three years for patients with advanced BTC. (April 2024) |
lynparza
Evento | Comentario | ||
Presentation: SGO | DUO-E (lynparza y Imfinzi) | Post-hoc exploratory subgroup analysis of the Phase III DUO-E trial, presented at SGO, assessed patients by mismatch repair status and demonstrated that median duration of response in proficient mismatch repair patients in the lynparza y Imfinzi arm was more than double versus the control arm (18.7 versus 7.6 months) in patients with advanced or recurrent endometrial cancer. (March 2024) |
Enhertu
Evento | Comentario | ||
Aprobación | US
|
| For the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior systemic treatment and have no satisfactory alternative treatment options (DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02, April 2024) |
Truqap
Evento | Comentario | ||
Aprobación | Japón
|
| En combinación con Faslodex for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1o PTEN-altered HR-positive, HER2-negative breast cancer following progression after treatment with endocrine therapy. (CAPItello-291, March 2024) |
Biofarmacéuticos - I+i
fasenra
Evento | Comentario | ||
Label expansion
| US | fasenra's approval in severe eosinophilic asthma has been expanded to include patients 6 years and older, from the previous 12 years and older (TATE, April 2024) | |
publicación (Neumología) | MILAGRO | Results from the MIRACLE Phase III trial showed treatment with fasenra resulted in a reduction of 74% in annual exacerbation rate in patients in Asia with severe eosinophilic asthma (April 2024) |
Enfermedad rara
AstraZeneca presented new clinical and real-world data from its leading rare neurology portfolio at the American Academy of Neurology (AAN) Annual Meeting in Denver, CO, 13 to 18 April 2024. The Company presented 14 abstracts, including five oral presentations, across both gMG and NMOSD.
Ultomiris
Evento | Comentario | ||
Aprobación | US |
| For the treatment of adult patients with anti-aquaporin-4 antibody-positive (Ab+) NMOSD. (CHAMPION-NMOSD, March 2024) |
Voydeya
Evento | Comentario | ||
Aprobación | US |
| For the treatment of extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria, as add-on therapy to Ultomiris or Soliris. (ALPHA, April 2024) |
Aprobación | EU |
| For the treatment of adult patients with paroxysmal nocturnal haemoglobinuria who have residual haemolytic anaemia, as an add-on therapy to Ultomiris or Soliris. (ALPHA, February 2024). |
Estados financieros intermedios
Mesa 17: Estado consolidado condensado del resultado integral: 1T 2024
Para el trimestre terminó el 31 de marzo |
| 2024 | 2023 |
|
| $m | $m |
Los ingresos totales |
| 12,679 | 10,879 |
Venta de productos |
| 12,177 | 10,566 |
Ingresos de la Alianza |
| 457 | 286 |
Ingresos por colaboración |
| 45 | 27 |
El costo de ventas | (2,218) | (1,905) | |
Beneficio bruto |
| 10,461 | 8,974 |
Gasto de distribución | (135) | (134) | |
Gastos de investigación y desarrollo | (2,783) | (2,611) | |
Gastos de venta, generales y administrativos | (4,495) | (4,059) | |
Otros ingresos y gastos operativos | 67 | 379 | |
Beneficio operativo |
| 3,115 | 2,549 |
Ingresos financieros | 111 | 78 | |
Gastos financieros | (413) | (365) | |
Participación en pérdidas después de impuestos en asociadas y negocios conjuntos | (13) | - | |
Beneficio antes de impuestos |
| 2,800 | 2,262 |
Taxation | (620) | (458) | |
Beneficio del período |
| 2,180 | 1,804 |
Otro resultado integral: |
|
|
|
Partidas que no se reclasificarán a resultados: |
|
|
|
Remedición del pasivo por pensiones por prestaciones definidas | 144 | (10) | |
Net gains on equity investments measured at fair value through other comprehensive income | 35 | 46 | |
Movimientos del valor razonable relacionados con el riesgo crediticio propio de los bonos designados como valor razonable con cambios en resultados | - | 2 | |
Impuesto sobre elementos que no se reclasificarán a resultados | (39) | 24 | |
|
| 140 | 62 |
Partidas que pueden reclasificarse posteriormente a resultados: | |||
Tipo de cambio procedente de la consolidación | (515) | 314 | |
Tipo de cambio que surge de pasivos designados en coberturas de inversión netas | (98) | (7) | |
Movimientos de valor razonable en coberturas de flujos de efectivo | (86) | 56 | |
Movimientos del valor razonable en coberturas de flujos de efectivo transferidos a resultados | 70 | (75) | |
Movimientos del valor razonable de los derivados designados en las coberturas de inversión neta | 22 | 16 | |
Costos de cobertura | 15 | - | |
Impuesto sobre partidas que puedan reclasificarse posteriormente a resultados | 35 | 12 | |
(557) | 316 | ||
Otros (gastos) / ingresos integrales, neto de impuestos |
| (417) | 378 |
Resultado integral total del período |
| 1,763 | 2,182 |
Beneficio atribuible a: | |||
Propietarios del padre | 2,179 | 1,803 | |
Participaciones no controladoras | 1 | 1 | |
2,180 | 1,804 | ||
Resultado integral total atribuible a: | |||
Propietarios del padre | 1,762 | 2,181 | |
Participaciones no controladoras | 1 | 1 | |
1,763 | 2,182 | ||
Ganancias básicas por acción ordinaria de $ 0.25 | $1.41 | $1.16 | |
Ganancias diluidas por acción ordinaria de $ 0.25 | $1.40 | $1.16 | |
Número medio ponderado de acciones ordinarias en emisión (millones) | 1,549 | 1,549 | |
Promedio ponderado diluido de Acciones Ordinarias en emisión (millones) | 1,560 | 1,560 |
Mesa 18: Estado de situación financiera consolidado condensado
| A las 31 mar 2024 | Al 31 dic 2023 | A las 31 mar 2023 | |
| $m | $m | $m | |
Activos | ||||
Activos no corrientes | ||||
Propiedad, planta y equipo. | 9,411 | 9,402 | 8,644 | |
Activos por derecho de uso | 1,205 | 1,100 | 955 | |
Goodwill | 19,978 | 20,048 | 20,001 | |
Activos intangibles | 38,834 | 38,089 | 39,291 | |
Inversiones en asociadas y negocios conjuntos | 130 | 147 | 77 | |
Otras inversiones | 1,565 | 1,530 | 1,157 | |
Instrumentos financieros derivados | 213 | 228 | 116 | |
Otros ingresos | 745 | 803 | 682 | |
Activos por impuestos diferidos | 4,618 | 4,718 | 3,498 | |
| 76,699 | 76,065 | 74,421 | |
Activos circulantes | ||||
Los inventarios | 5,337 | 5,424 | 4,967 | |
Cuentas comerciales y otras cuentas por cobrar | 11,072 | 12,126 | 10,289 | |
Otras inversiones | 180 | 122 | 230 | |
Instrumentos financieros derivados | 11 | 116 | 40 | |
Impuesto sobre la renta por cobrar | 1,153 | 1,426 | 508 | |
Efectivo y equivalentes de efectivo | 7,841 | 5,840 | 6,232 | |
| 25,594 | 25,054 | 22,266 | |
los activos totales |
| 102,293 | 101,119 | 96,687 |
Pasivos |
|
|
|
|
Pasivo circulante | ||||
Préstamos y empréstitos que devengan intereses | (6,050) | (5,129) | (3,625) | |
Pasivos por arrendamiento | (281) | (271) | (232) | |
Comerciales y otras cuentas a pagar | (19,699) | (22,374) | (19,210) | |
Instrumentos financieros derivados | (92) | (156) | (44) | |
Provisiones | (1,148) | (1,028) | (546) | |
Impuesto sobre la Renta por pagar | (1,631) | (1,584) | (1,203) | |
| (28,901) | (30,542) | (24,860) | |
Pasivos no corrientes | ||||
Préstamos y empréstitos que devengan intereses | (27,259) | (22,365) | (26,916) | |
Pasivos por arrendamiento | (961) | (857) | (730) | |
Instrumentos financieros derivados | (51) | (38) | (133) | |
Pasivos por impuestos diferidos | (2,621) | (2,844) | (2,795) | |
Obligaciones por beneficios de jubilación | (1,280) | (1,520) | (1,128) | |
Provisiones | (1,123) | (1,127) | (914) | |
Otras cuentas por pagar | (2,596) | (2,660) | (3,400) | |
(35,891) | (31,411) | (36,016) | ||
Pasivos totales |
| (64,792) | (61,953) | (60,876) |
Activos netos |
| 37,501 | 39,166 | 35,811 |
Equidad | ||||
Capital y reservas atribuibles a los accionistas de la Sociedad Dominante | ||||
Capital social | 388 | 388 | 387 | |
Compartir cuenta premium | 35,194 | 35,188 | 35,159 | |
Otras reservas | 2,075 | 2,065 | 2,068 | |
Ganancias retenidas | (212) | 1,502 | (1,825) | |
| 37,445 | 39,143 | 35,789 | |
Participaciones no controladoras | 56 | 23 | 22 | |
Equidad total |
| 37,501 | 39,166 | 35,811 |
Mesa 19: Estado de cambios en el patrimonio neto resumido consolidado
Capital social | Compartir cuenta premium | Otras reservas | Ganancias retenidas | Total atribuible a los propietarios de el padre | Participaciones no controladoras | Equidad total | ||
| $m | $m | $m | $m | $m | $m | $m | |
A 1 de enero de 2023 | 387 | 35,155 | 2,069 | (574) | 37,037 | 21 | 37,058 | |
Beneficio del período | - | - | - | 1,803 | 1,803 | 1 | 1,804 | |
Otro resultado integral | - | - | - | 378 | 378 | - | 378 | |
Transferencia a otras reservas | - | - | (1) | 1 | - | - | - | |
Transacciones con propietarios | ||||||||
Dividendos | - | - | - | (3,047) | (3,047) | - | (3,047) | |
Emisión de acciones ordinarias | - | 4 | - | - | 4 | - | 4 | |
Cargo por pagos basados en acciones para el período | - | - | - | 132 | 132 | - | 132 | |
Liquidación de adjudicaciones de planes de acciones | - | - | - | (518) | (518) | - | (518) | |
Movimiento neto |
| - | 4 | (1) | (1,251) | (1,248) | 1 | (1,247) |
Al 31 mar 2023 |
| 387 | 35,159 | 2,068 | (1,825) | 35,789 | 22 | 35,811 |
|
|
|
|
|
|
|
|
|
A 1 de enero de 2024 |
| 388 | 35,188 | 2,065 | 1,502 | 39,143 | 23 | 39,166 |
Beneficio del período | - | - | - | 2,179 | 2,179 | 1 | 2,180 | |
Otro gasto integral | - | - | - | (417) | (417) | - | (417) | |
Transferencia a otras reservas | - | - | 10 | (10) | - | - | - | |
Transacciones con propietarios | ||||||||
Dividendos | - | - | - | (3,052) | (3,052) | - | (3,052) | |
Emisión de acciones ordinarias | - | 6 | - | - | 6 | - | 6 | |
Cambios en participaciones no controladoras | - | - | - | - | - | 32 | 32 | |
Cargo por pagos basados en acciones para el período | - | - | - | 159 | 159 | - | 159 | |
Liquidación de adjudicaciones de planes de acciones | - | - | - | (573) | (573) | - | (573) | |
Movimiento neto | - | 6 | 10 | (1,714) | (1,698) | 33 | (1,665) | |
Al 31 mar 2024 |
| 388 | 35,194 | 2,075 | (212) | 37,445 | 56 | 37,501 |
Mesa 20: Estado de flujos de efectivo resumido consolidado
Para el trimestre terminó el 31 de marzo | 2024 | 2023 | |
$m | $m |
flujos de efectivo por actividades operacionales | |||
Beneficio antes de impuestos | 2,800 | 2,262 | |
Ingresos y gastos financieros | 302 | 287 | |
Participación en pérdidas después de impuestos de asociadas y negocios conjuntos | 13 | - | |
Depreciación, amortización y deterioro | 1,255 | 1,502 | |
Movement in working capital and short-term provisions | (455) | 242 | |
Ganancias por enajenación de activos intangibles | - | (249) | |
Movimientos del valor razonable sobre contraprestaciones contingentes que surgen de combinaciones de negocios | 16 | - | |
Movimientos no monetarios y otros | (674) | (429) | |
Efectivo generado por operaciones |
| 3,257 | 3,615 |
Pago interesado | (341) | (257) | |
Impuesto pagado | (430) | (225) | |
Entrada neta de efectivo de las actividades operativas |
| 2,486 | 3,133 |
Flujos de efectivo de actividades de inversión |
| ||
Adquisición de subsidiarias, neto de efectivo adquirido | (726) | (189) | |
Pagos al momento de la concesión de acciones a los empleados atribuibles a combinaciones de negocios | - | (23) | |
Pago de contraprestación contingente de combinaciones de negocios | (222) | (214) | |
Compra de propiedad, planta y equipo | (417) | (247) | |
Enajenación de propiedades, planta y equipo | 53 | 125 | |
Compra de activos intangibles | (1,188) | (1,223) | |
Enajenación de activos intangibles | 75 | 264 | |
Movimiento en el pasivo por participación en las ganancias | - | 175 | |
Compra de inversiones en activos no corrientes | (41) | - | |
Enajenación de inversiones en activos no corrientes | 9 | 10 | |
Movimiento en inversiones a corto plazo, depósitos fijos y otros instrumentos de inversión | (57) | 9 | |
Enajenación de inversiones en asociadas y negocios conjuntos | 8 | - | |
Interés recibido | 93 | 67 | |
Salida neta de efectivo de las actividades de inversión | (2,413) | (1,246) | |
Entrada neta de efectivo antes de actividades de financiación |
| 73 | 1,887 |
Flujos de efectivo de actividades de financiación | |||
Producto de la emisión de capital social | 6 | 4 | |
Emisión de préstamos y empréstitos | 4,976 | 3,826 | |
Reembolso de préstamos y empréstitos | (7) | (2,004) | |
Dividendos pagados | (3,033) | (3,047) | |
Contratos de cobertura relacionados con el pago de dividendos | (8) | 27 | |
Amortización de obligaciones derivadas de arrendamientos | (74) | (67) | |
Movimiento en préstamos a corto plazo | 1,001 | 97 | |
Pago del pasivo de compra de acciones de Acerta Pharma | (833) | (867) | |
Entradas / (salidas) netas de efectivo de actividades de financiación |
| 2,028 | (2,031) |
Net increase/(decrease) in Cash and cash equivalents in the period | 2,101 | (144) | |
Efectivo y equivalentes de efectivo al comienzo del período | 5,637 | 5,983 | |
Efectos del tipo de cambio | (46) | (11) | |
Efectivo y equivalentes de efectivo al final del período |
| 7,692 | 5,828 |
El efectivo y equivalentes de efectivo consisten en: | |||
Efectivo y equivalentes de efectivo | 7,841 | 6,232 | |
Sobregiros | (149) | (404) | |
|
| 7,692 | 5,828 |
Notas a los estados financieros intermedios
Nota 1: Bases de elaboración y políticas contables
These unaudited condensed consolidated Interim financial statements for the three months ended 31 March 2024 have been prepared in accordance with International Accounting Standard 34, 'Interim Financial Reporting' (IAS 34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union, UK-adopted IAS 34 and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom's Financial Conduct Authority and with the requirements of the Companies Act 2006 as applicable to companies reporting under those standards.
The unaudited Interim financial statements for the three months ended 31 March 2024 were approved by the Board of Directors for publication on 25 April 2024.
This results announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The annual financial statements of the Group for the year ended 31 December 2023 were prepared in accordance with UK-adopted international accounting standards and with the requirements of the Companies Act 2006. The annual financial statements also comply fully with IFRS Accounting Standards as issued by the IASB and International Accounting Standards as adopted by the European Union. Except for the estimation of the interim income tax charge, the Interim financial statements have been prepared applying the accounting policies that were applied in the preparation of the Group's published consolidated financial statements for the year ended 31 December 2023.
The comparative figures for the financial year ended 31 December 2023 are not the Group's statutory accounts for that financial year. Those accounts have been reported on by the Group's auditors and will be delivered to the Registrar of Companies; their report was (i) unqualified, (ii) did not include a reference to any matters to which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006.
Preocupación continua
The Group has considerable financial resources available. As at 31 March 2024, the Group has $14.7bn in financial resources (cash and cash equivalent balances of $7.8bn and undrawn committed bank facilities of $6.9bn, with $6.3bn of borrowings due within one year). These facilities contain no financial covenants and were undrawn at 31 March 2024. $2bn of the facilities are available until February 2025 and the other $4.9bn are available until April 2029.
The Group's revenues are largely derived from sales of medicines covered by patents, which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to adversely affect revenues in some of our significant markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas.
En consecuencia, los Directores creen que, en general, el Grupo está bien posicionado para gestionar sus riesgos comerciales con éxito. En consecuencia, continúan adoptando el principio de empresa en funcionamiento al preparar los estados financieros intermedios.
Procedimientos legales
La información contenida en la Nota 6 actualiza las revelaciones relativas a procesos judiciales y pasivos contingentes en los Annual Report and Form 20-F Information 2023.
Nota 2: Activos intangibles
In accordance with IAS 36 'Impairment of Assets', reviews for triggers of impairment or impairment reversals at an individual asset or cash generating unit level were conducted, and impairment tests carried out where triggers were identified. This review resulted in $nil impairment charge during the three months ended 31 March 2024 (31 March 2023: $271m net charge). In Q1 2023, net impairment charges included the $244m impairment of the ALXN1840 intangible asset, following the decision to discontinue this development programme in Wilson's disease.
The acquisition of Icosavax, Inc. completed on 19 February 2024. The transaction is recorded as an asset acquisition based on the concentration test permitted under IFRS 3 'Business Combinations', with consideration of $841m principally relating to $639m of intangible assets, $141m of cash and cash equivalents and $51m of marketable securities. Contingent consideration of up to $300m could be paid on achievement of regulatory and sales milestones; these potential liabilities would be recorded when relevant milestones are triggered or performance conditions satisfied.
Nota 3: Deuda neta
The table below provides an analysis of Net debt and a reconciliation of Net Cash flow to the movement in Net debt. The Group monitors Net debt as part of its capital management policy as described in Note 28 of the Informe anual e información del formulario 20-F 2023. Net debt is a non-GAAP financial measure.
Mesa 21: Deuda neta
| A 1 de enero de 2024 | Flujo de fondos | Adquisiciones | No en efectivo | Movimientos cambiarios | Al 31 mar 2024 | |
| $m | $m | $m | $m | $m | $m | |
Cuotas no corrientes de préstamos | (22,365) | (4,976) | (3) | (2) | 87 | (27,259) | |
Cuotas no corrientes de arrendamientos | (857) | - | (2) | (114) | 12 | (961) | |
Deuda total a largo plazo |
| (23,222) | (4,976) | (5) | (116) | 99 | (28,220) |
Cuotas vigentes de préstamos | (4,614) | 7 | (9) | (1) | 24 | (4,593) | |
Cuotas vigentes de arrendamientos | (271) | 86 | (2) | (100) | 6 | (281) | |
Papel comercial | - | (980) | - | - | - | (980) | |
Garantía bancaria recibida | (215) | 60 | - | - | - | (155) | |
Otros préstamos a corto plazo, excluidos los descubiertos | (97) | (81) | - | - | 5 | (173) | |
Sobregiros | (203) | 54 | - | - | - | (149) | |
Deuda corriente total |
| (5,400) | (854) | (11) | (101) | 35 | (6,331) |
Préstamos brutos |
| (28,622) | (5,830) | (16) | (217) | 134 | (34,551) |
Instrumentos financieros derivados netos | 150 | 8 | - | (77) | - | 81 | |
Préstamos netos |
| (28,472) | (5,822) | (16) | (294) | 134 | (34,470) |
Efectivo y equivalentes de efectivo | 5,840 | 1,837 | 209 | 1 | (46) | 7,841 | |
Otras inversiones - corriente | 122 | 57 | 3 | - | (2) | 180 | |
Efectivo e inversiones |
| 5,962 | 1,894 | 212 | 1 | (48) | 8,021 |
Deuda neta |
| (22,510) | (3,928) | 196 | (293) | 86 | (26,449) |
Net debt increased by $3,939m in the three months to 31 March 2024 to $26,449m. Details of the committed undrawn bank facilities are disclosed within the going concern section of Note 1. Non-cash movements in the period include fair value adjustments under IFRS 9 'Financial Instruments'.
In February 2024, AstraZeneca issued the following:
- $1,250m of fixed-rate notes with a coupon of 4.8% maturing in February 2027
- $1,250m of fixed-rate notes with a coupon of 4.85% maturing in February 2029
- $1,000m of fixed-rate notes with a coupon of 4.9% maturing in February 2031
- $1,500m of fixed-rate notes with a coupon of 5% maturing in February 2034
-
The Group has agreements with some bank counterparties whereby the parties agree to post cash collateral on financial derivatives, for the benefit of the other, equivalent to the market valuation of the derivative positions above a predetermined threshold. The carrying value of such cash collateral held by the Group at 31 March 2024 was $155m (31 December 2023: $215m) and the carrying value of such cash collateral posted by the Group at 31 March 2024 was $136m (31 December 2023: $102m).
The equivalent GAAP measure to Net debt is 'liabilities arising from financing activities', which excludes the amounts for cash and overdrafts, other investments and non-financing derivatives shown above and includes the Acerta Pharma share purchase liability of $nil (31 December 2023: $833m).
During the quarter ended 31 March 2024, there have been no changes to the Company's solicited long term credit ratings. Moody's credit ratings were long term: A2; short term: P-1. Standard and Poor's credit ratings were long term: A; short term: A-1.
Nota 4: Instrumentos Financieros
Como se detalla en los estados financieros anuales más recientes del Grupo, los principales instrumentos financieros consisten en instrumentos financieros derivados, otras inversiones, cuentas por cobrar comerciales y otras, efectivo y equivalentes de efectivo, cuentas por pagar comerciales y otras, pasivos por arrendamiento y préstamos y empréstitos que devengan intereses.
The Group has certain equity investments that are categorised as Level 3 in the fair value hierarchy that are held at $309m at (31 December 2023: $313m) and for which a fair value loss of $1m has been recognised in the three months ended 31 March 2024 (31 March 2023: fair value gain of $1m). In the absence of specific market data, these unlisted investments are held at fair value based on the cost of investment and adjusted as necessary for impairments and revaluations on new funding rounds, which are seen to approximate the fair value. All other fair value gains and/or losses that are presented in Net gains on equity investments measured at fair value through other comprehensive income in the Condensed consolidated statement of comprehensive income for the three months ended 31 March 2024 are Level 1 fair value measurements, valued based on quoted prices in active markets.
Financial instruments measured at fair value include $1,605m of other investments, $5,504m held in money-market funds and $81m of derivatives as at 31 March 2024. With the exception of derivatives being Level 2 fair valued, and certain equity investments of $320m categorised as Level 3, the aforementioned balances are Level 1 fair valued. Financial instruments measured at amortised cost include $136m of cash collateral pledged to counterparties. The total fair value of interest-bearing loans and borrowings at 31 March 2024, which have a carrying value of $34,551m in the Condensed consolidated statement of financial position, was $33,364m.
Mesa 22: Instrumentos financieros - contraprestación contingente
| 2024 |
| 2023 |
|
| Alianza de diabetes | Otro | Total | Total |
|
| $m | $m | $m | $m |
Al 1 de enero | 1,945 | 192 | 2,137 | 2,222 | |
Adiciones mediante combinaciones de negocios | - | 54 | 54 | 60 | |
Asentamientos | (221) | (1) | (222) | (214) | |
Revalorizaciones | - | 16 | 16 | - | |
Descuento relajarse | 26 | 2 | 28 | 33 | |
Al 31 de marzo |
| 1,750 | 263 | 2,013 | 2,101 |
La contraprestación contingente que surge de combinaciones de negocios se valora razonablemente utilizando un análisis de árbol de decisiones, con datos clave que incluyen la probabilidad de éxito, la consideración de posibles retrasos y los niveles esperados de ingresos futuros.
El saldo de contraprestación contingente relacionado con la participación de BMS en la alianza mundial de diabetes de 1,750 millones de dólares (31 de diciembre de 2023: 1,945 millones de dólares) aumentaría/disminuiría en 175 millones de dólares con un aumento/disminución de las ventas del 10%, en comparación con las estimaciones actuales.
Note 5: Business combinations
The acquisition of Gracell Biotechnologies, Inc. completed on 22 February 2024 and was recorded as a business combination using the acquisition method of accounting in accordance with IFRS 3 'Business Combinations'. Consequently the assets acquired, and liabilities assumed are recorded at fair value. Given the proximity of the completion of the transaction to the reporting date, the identification and determination of the fair values related to the acquired balance sheet is on-going. This exercise is expected to complete in Q2 2024 with the majority of the fair value expected to be allocated to the intangible assets, as currently reported. The upfront cash portion of the consideration represents a transaction value of approximately $1.0bn. Combined, the upfront and potential contingent value payments if achieved, represent, a transaction value of approximately $1.2bn. The cash and cash equivalents acquired on Gracell's balance sheet, totalled to $209m at the close of the transaction.
Nota 6: Procesos judiciales y pasivos contingentes
AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and investigations, including Government investigations, relating to product liability, commercial disputes, infringement of propiedad property (IP) rights, the validity of certain patents, anti-trust law and sales and marketing practices. The matters discussed below constitute the more significant developments since publication of the disclosures concerning legal proceedings in the Company's Annual Report and Form 20-F Information 2023 (the Disclosures). Information about the nature and facts of the cases is disclosed in accordance with IAS 37.
Como se discutió en las Divulgaciones, la mayoría de los reclamos involucran asuntos altamente complejos. A menudo, estos problemas están sujetos a incertidumbres sustanciales y, por lo tanto, es difícil determinar la probabilidad de que se produzca una pérdida, si la hubiera, y/o una estimación del monto de cualquier pérdida.
En casos que han sido resueltos o adjudicados, o donde se han evaluado multas y sanciones cuantificables y que no están sujetas a apelación, o donde una pérdida es probable y podemos hacer una estimación razonable de la pérdida, AstraZeneca registra la pérdida absorbida. o hace una provisión para su mejor estimación de la pérdida esperada. La posición podría cambiar con el tiempo y las estimaciones que hizo la Compañía, y en las que la Compañía se ha basado para calcular estas provisiones, son inherentemente imprecisas. Por lo tanto, no puede haber garantía de que las pérdidas que resulten del resultado de cualquier procedimiento judicial no exceda el monto de las provisiones que se han registrado en las cuentas. Los principales factores que causan esta incertidumbre se describen con más detalle en las Divulgaciones y en el presente.
AstraZeneca tiene plena confianza en su propiedad intelectual y la defenderá y aplicará enérgicamente.
Matters disclosed in respect of the first quarter of 2024 and to 25 April 2024
Litigio de patentes
Legal proceedings brought against AstraZeneca considered to be contingent liabilities
Fórxiga
UK patent proceedings
In the UK, one of AstraZeneca's patents relating to Fórxiga is being challenged by Generics (UK) Limited, Teva Pharmaceutical Industries Limited, and Glenmark Pharmaceuticals Europe Limited. Trial is scheduled for March 2025.
Tagrisso
Procedimientos de patente de EE. UU.
In September 2021, Puma Biotechnology, Inc. (Puma) and Wyeth LLC (Wyeth) filed a patent infringement lawsuit in the US District Court for the District of Delaware (District Court) against AstraZeneca relating to Tagrisso. In March 2024, the District Court dismissed Puma. A trial, with Wyeth as the plaintiff, has been scheduled for May 2024.
Legal proceedings brought by AstraZeneca considered to be contingent assets
Calcuencia
Procedimientos de patente de EE. UU.
In February 2022, in response to Paragraph IV notices from multiple ANDA filers, AstraZeneca filed patent infringement lawsuits in the US District Court for the District of Delaware (District Court). In its complaint, AstraZeneca alleged that a generic version of Calcuencia capsules, if approved and marketed, would infringe patents that are owned or licensed by AstraZeneca. Trial is scheduled for March 2025.
In March and April 2024, AstraZeneca entered into settlement agreements with generic manufacturers, Sandoz Inc., and Natco Pharma Limited with Natco Pharma Inc., resulting in dismissal of the corresponding Calcuencia capsule ANDA litigation proceedings. Additional Calcuencia capsule ANDA litigation proceedings with the remaining three generic manufacturers are ongoing in the District Court.
In April 2024, AstraZeneca received a Paragraph IV notice from an ANDA filer relating to patents listed in the FDA Orange Book with reference to Calcuencia tablets. AstraZeneca is considering its response.
Lokelma
Procedimientos de patente de EE. UU.
In August 2022, in response to Paragraph IV notices, AstraZeneca initiated ANDA litigation against multiple generic filers in the US District Court for the District of Delaware (District Court). Trial is scheduled for March 2025.
AstraZeneca entered into a settlement agreement with a generic manufacturer, Alkem Laboratories, which resulted in dismissal of the corresponding litigation. Additional proceedings with the remaining generic manufacturers are ongoing in the District Court.
Soliris
Procedimientos de patente de EE. UU.
In January 2024, Alexion initiated patent infringement litigation against Samsung Bioepis Co. Ltd. (Samsung) in the US District Court for the District of Delaware alleging that Samsung's biosimilar eculizumab product, for which Samsung is currently seeking FDA approval, will infringe six Soliris-related patents. No trial date has been scheduled. Five of the six asserted patents are also the subject of entre partes review proceedings before the US Patent and Trademark Office. In February 2024, Alexion filed a motion for a preliminary injunction seeking to enjoin Samsung from launching its biosimilar eculizumab product upon FDA approval. A hearing on Alexion's preliminary injunction motion is scheduled for May 2024.
European patent proceedings
In March 2024, Alexion filed motions for preliminary injunctions against Amgen and Samsung at the Hamburg Local Division of the Unified Patent Court on the basis that Amgen's and Samsung's biosimilar eculizumab products infringe Alexion's eculizumab molecule patent that is expected to grant in Q2 2024. No hearing date for the preliminary injunction motions has been set.
Tagrisso
Russia patent proceedings
In Russia, in August 2023, AstraZeneca filed lawsuits in the Arbitration Court of the Moscow Region (Court) against the Ministry of Health of the Russian Federation and Axelpharm LLC (Axelpharm) related to Axelpharm's improper use of AstraZeneca's information to obtain authorisation to market a generic version of Tagrisso. In December 2023, the Court dismissed the lawsuit against the Ministry of Health of the Russian Federation. In January 2024, AstraZeneca filed an appeal, and the appellate court affirmed the dismissal in March 2024. The lawsuit against Axelpharm remains pending.
In Russia, in November 2023, Axelpharm filed a compulsory licensing action against AstraZeneca in the Court related to a patent that covers Tagrisso. The compulsory licensing action remains pending.
Litigio de responsabilidad por productos
Legal proceedings brought against AstraZeneca for which a provision has been taken
Nexium y Losec/Prilosec
Procedimientos en EE. UU.
AstraZeneca has been defending lawsuits brought in federal and state courts involving claims that plaintiffs have been diagnosed with various injuries following treatment with proton pump inhibitors (PPIs), including Nexium y Prilosec. Most of the lawsuits alleged kidney injury. In August 2017, the pending federal court cases were consolidated into a multidistrict litigation (MDL) proceeding in the US District Court for the District of New Jersey for pre-trial purposes. Cases alleging kidney injury were also filed in Delaware and New Jersey state courts.
In addition, AstraZeneca has been defending lawsuits involving allegations of gastric cancer following treatment with PPIs, including one such claim in the US District Court for the Middle District of Louisiana (Louisiana District Court).
In October 2023, AstraZeneca resolved all pending claims in the MDL, as well as all pending claims in Delaware and New Jersey state courts, for $425M, for which a provision has been taken. The only remaining case is the one pending in the Louisiana District Court, which is scheduled for trial in January 2025.
Procedimientos de Canadá
In Canada, in July and August 2017, AstraZeneca was served with three putative class action lawsuits. Two of the lawsuits have been dismissed, one in 2019 and one in 2021. The third lawsuit seeks authorisation to represent individual residents in Canada who allegedly suffered kidney injuries from the use of proton pump inhibitors, including Nexium y Losec.
Legal proceedings brought against AstraZeneca considered to be contingent liabilities
Onglyza y Kombiglyze
Procedimientos en EE. UU.
In the US, AstraZeneca has been defending various lawsuits in both California state court and in a consolidated federal proceeding alleging heart failure, cardiac injuries, and/or death from treatment with Onglyza or Kombiglyze. In the California state court proceeding, the trial court granted summary judgment for AstraZeneca, which the California appellate court affirmed. The California Supreme Court has declined further review, and the California matter has concluded. The consolidated federal cases were dismissed in August 2022 by the US District Court for the Eastern District of Kentucky. That dismissal was affirmed by the US Court of Appeals for the Sixth Circuit in February 2024.
Vaxzevria
UK proceedings
AstraZeneca is defending lawsuits in the UK involving multiple claimants alleging injuries following vaccination with AstraZeneca's COVID-19 vaccine. Most of the lawsuits involve claims of thrombosis with thrombocytopenia syndrome. No trial dates have been scheduled.
Litigio comercial
Legal proceedings brought against AstraZeneca considered to be contingent liabilities
340B Antitrust Litigation
Procedimientos en EE. UU.
In September 2021, AstraZeneca was served with a class-action antitrust complaint filed in the US District Court for the Western District of New York (District Court) by Mosaic Health alleging a conspiracy to restrict access to 340B discounts in the diabetes market through contract pharmacies. In September 2022, the District Court granted AstraZeneca's motion to dismiss the Complaint. In February 2024, the District Court denied Plaintiffs' request to file an amended complaint and entered an order closing the matter. In March 2024, Plaintiffs filed an appeal.
Definiciones
Germany proceedings
In Germany, in July 2020, AstraZeneca received a notice of arbitration filed with the German Institution of Arbitration from the sellers of Definiens AG (the Sellers) regarding the 2014 Share Purchase Agreement (SPA) between AstraZeneca and the Sellers. The Sellers claim that they are owed approximately $140m in earn-outs under the SPA. In December 2023, after an arbitration hearing, the arbitration panel made a final award of $46.43m in favour of the Sellers. In March 2024, AstraZeneca filed an application with the Bavarian Supreme Court to set aside the arbitration award.
Legal proceedings brought by AstraZeneca considered to be contingent assets
Disputa por regalías sobre inhibidores de PARP
UK proceedings
In October 2012, Tesaro, Inc. (now wholly owned by GlaxoSmithKline plc, (GSK)) entered into two worldwide, royalty-bearing patent license agreements with AstraZeneca related to GSK's product niraparib. In May 2021, AstraZeneca filed a lawsuit against GSK in the Commercial Court of England and Wales alleging that GSK had failed to pay all of the royalties due on niraparib sales under the license agreements. In April 2023, after trial, the trial court issued a decision in AstraZeneca's favour. In February 2024, Court of Appeal reversed. In March 2024, AstraZeneca filed a request for permission to appeal with the Supreme Court of the United Kingdom.
Investigaciones / procedimientos gubernamentales
Legal proceedings brought against AstraZeneca considered to be contingent liabilities
340B Qui Tam
Procedimientos en EE. UU.
In July 2023, AstraZeneca was served with an unsealed civil lawsuit brought by a qui tam relator on behalf of the United States, several states, and the District of Columbia in the US District Court for the Central District of California (District Court). The complaint alleges that AstraZeneca violated the US False Claims Act and state law analogues. In March 2024, the District Court granted AstraZeneca's motion to dismiss the First Amended Complaint without leave to amend. In April 2024, the relator filed an appeal.
Legal proceedings brought by AstraZeneca considered to be contingent assets
Litigio sobre la Ley de Reducción de la Inflación
Procedimientos en EE. UU.
In August 2023, AstraZeneca filed a lawsuit in the US District Court for the District of Delaware (District Court) against the US Department of Health and Human Services (HHS) challenging aspects of the drug price negotiation provisions of the Inflation Reduction Act and the implementing guidance and regulations. In March 2024, the District Court granted HHS' motions and dismissed AstraZeneca's lawsuit.
Arkansas 340B Litigation
Procedimientos en EE. UU.
In March 2024, AstraZeneca filed a lawsuit against the State of Arkansas alleging that the Arkansas's 340B statute is pre-empted by federal law and unconstitutional.
Otro
Additional government inquiries
As is true for most, if not all, major prescription pharmaceutical companies, AstraZeneca is currently involved in multiple inquiries into drug marketing and pricing practices. In addition to the investigations described above, various law enforcement offices have, from time to time, requested information from the Group. There have been no material developments in those matters.
notas 7
Mesa 23: Tercer trimestre de 1: análisis interanual de ventas de productos[ 13 ]
| World | US | Mercados Emergentes | Europa | DdV establecido |
$m | % cambio real | % variación CER | $m | % de variación | $m | % cambio real | % variación CER | $m | % cambio real | % variación CER | $m | % cambio real | % variación CER | |
Oncología | 4,760 | 21 | 24 | 2,084 | 22 | 1,202 | 24 | 33 | 953 | 26 | 23 | 521 | 6 | 16 |
Tagrisso | 1,595 | 12 | 15 | 623 | 20 | 488 | 10 | 17 | 302 | 18 | 15 | 182 | (10) | (2) |
Imfinzi | 1,113 | 29 | 33 | 582 | 19 | 129 | 59 | 83 | 232 | 43 | 40 | 170 | 31 | 45 |
Calcuencia | 718 | 35 | 35 | 494 | 29 | 39 | Nuevo Méjico | Nuevo Méjico | 153 | 42 | 39 | 32 | 44 | 47 |
lynparza | 705 | 8 | 11 | 288 | 7 | 167 | 23 | 33 | 191 | 7 | 5 | 59 | (13) | (6) |
Enhertu | 122 | Nuevo Méjico | Nuevo Méjico | - | - | 83 | Nuevo Méjico | Nuevo Méjico | 26 | Nuevo Méjico | Nuevo Méjico | 13 | Nuevo Méjico | Nuevo Méjico |
Zoladex | 276 | 22 | 28 | 3 | 9 | 214 | 28 | 35 | 35 | 9 | 6 | 24 | (1) | 7 |
Imjudo | 62 | 67 | 70 | 39 | 22 | 4 | Nuevo Méjico | Nuevo Méjico | 8 | Nuevo Méjico | Nuevo Méjico | 11 | Nuevo Méjico | Nuevo Méjico |
Truqap | 50 | Nuevo Méjico | Nuevo Méjico | 50 | Nuevo Méjico | - | - | - | - | - | - | - | - | - |
Orpatías | 12 | 48 | 53 | - | - | 12 | 48 | 53 | - | - | - | - | - | - |
Otros | 107 | (24) | (19) | 5 | (10) | 66 | (24) | (20) | 6 | (52) | (53) | 30 | (16) | (7) |
Biofarmacéuticos: CVRM | 3,012 | 19 | 22 | 748 | 20 | 1,365 | 17 | 24 | 716 | 29 | 26 | 183 | (2) | 7 |
Farxiga | 1,845 | 42 | 45 | 473 | 60 | 711 | 43 | 50 | 553 | 41 | 37 | 108 | (4) | 5 |
Brilinta | 323 | (3) | (1) | 163 | (9) | 88 | 9 | 21 | 67 | (1) | (3) | 5 | (17) | (14) |
Crestor | 297 | (3) | 2 | 10 | (32) | 241 | - | 4 | 12 | (26) | (27) | 34 | 2 | 11 |
seloken/Toprol-XL | 165 | (8) | (2) | - | (96) | 161 | (7) | (2) | 3 | (23) | (23) | 1 | (39) | (36) |
Lokelma | 114 | 16 | 19 | 52 | (7) | 21 | 83 | 90 | 18 | 60 | 56 | 23 | 16 | 29 |
roxadustato | 75 | 24 | 28 | - | - | 75 | 24 | 28 | - | - | - | - | - | - |
Andexxa | 47 | 5 | 6 | 20 | (3) | 1 | Nuevo Méjico | Nuevo Méjico | 18 | 24 | 21 | 8 | (14) | (4) |
Wainua | 5 | Nuevo Méjico | Nuevo Méjico | 5 | Nuevo Méjico | - | - | - | - | - | - | - | - | - |
Otros | 141 | (33) | (31) | 25 | (55) | 67 | (32) | (27) | 45 | (11) | (12) | 4 | 3 | 5 |
Biofarmacéuticos: R&I | 1,804 | 14 | 16 | 737 | 19 | 588 | 10 | 16 | 330 | 13 | 11 | 149 | 6 | 11 |
SYMBICORT® | 769 | 12 | 14 | 299 | 28 | 253 | 11 | 18 | 142 | (3) | (6) | 75 | (5) | (3) |
fasenra | 358 | 6 | 6 | 210 | 4 | 22 | 53 | 61 | 93 | 6 | 4 | 33 | (6) | - |
Pulmicort | 224 | 2 | 5 | 5 | (52) | 191 | 5 | 9 | 20 | - | (3) | 8 | (7) | (4) |
Breztri | 219 | 52 | 54 | 105 | 30 | 70 | 83 | 91 | 30 | 97 | 93 | 14 | 43 | 53 |
Tezspire | 43 | Nuevo Méjico | Nuevo Méjico | - | - | 2 | Nuevo Méjico | Nuevo Méjico | 27 | Nuevo Méjico | Nuevo Méjico | 14 | Nuevo Méjico | Nuevo Méjico |
saphnelo | 91 | 94 | 95 | 83 | 89 | 1 | Nuevo Méjico | Nuevo Méjico | 4 | Nuevo Méjico | Nuevo Méjico | 3 | 80 | 99 |
Airsupra | 7 | Nuevo Méjico | Nuevo Méjico | 7 | Nuevo Méjico | - | - | - | - | - | - | - | - | - |
Otros | 93 | (30) | (29) | 28 | (41) | 49 | (30) | (27) | 14 | 3 | 1 | 2 | (17) | (15) |
Biofarmacéuticos: V&I | 212 | (40) | (40) | 27 | Nuevo Méjico | 90 | (13) | (12) | 74 | (27) | (26) | 21 | (87) | (86) |
Synagis | 171 | (13) | (13) | (1) | 76 | 90 | 16 | 18 | 61 | (25) | (27) | 21 | (46) | (43) |
beyfortus | 26 | Nuevo Méjico | Nuevo Méjico | 26 | Nuevo Méjico | - | - | - | - | - | - | - | - | - |
FluMist | 7 | Nuevo Méjico | Nuevo Méjico | 2 | Nuevo Méjico | - | 59 | 59 | 5 | Nuevo Méjico | Nuevo Méjico | - | Nuevo Méjico | Nuevo Méjico |
mAb de COVID-19 | 2 | (99) | (99) | - | - | - | Nuevo Méjico | Nuevo Méjico | 2 | (53) | (56) | - | Nuevo Méjico | Nuevo Méjico |
Otros | 6 | (79) | (80) | - | - | - | Nuevo Méjico | Nuevo Méjico | 6 | (42) | (43) | - | - | - |
Enfermedad rara | 2,096 | 12 | 16 | 1,207 | 10 | 251 | 45 | 73 | 401 | 4 | 1 | 237 | 12 | 21 |
Ultomiris | 859 | 32 | 34 | 482 | 27 | 32 | Nuevo Méjico | Nuevo Méjico | 202 | 27 | 24 | 143 | 46 | 61 |
Soliris | 739 | (11) | (8) | 411 | (8) | 125 | 9 | 37 | 142 | (22) | (24) | 61 | (30) | (28) |
Strensiq | 313 | 20 | 21 | 246 | 20 | 21 | 44 | 67 | 24 | 15 | 12 | 22 | 4 | 14 |
Koselugo | 132 | 68 | 82 | 46 | 13 | 59 | Nuevo Méjico | Nuevo Méjico | 18 | 72 | 69 | 9 | Nuevo Méjico | Nuevo Méjico |
Kanuma | 53 | 30 | 35 | 22 | 13 | 14 | Nuevo Méjico | Nuevo Méjico | 15 | 19 | 18 | 2 | (3) | 2 |
Otros medicamentos | 293 | (6) | 1 | 24 | (33) | 206 | - | 11 | 29 | 31 | 30 | 34 | (31) | (25) |
Nexium | 240 | (2) | 7 | 22 | (27) | 172 | 10 | 23 | 13 | 13 | 11 | 33 | (30) | (24) |
Otros | 53 | (23) | (21) | 2 | (63) | 34 | (31) | (29) | 16 | 52 | 52 | 1 | (53) | (49) |
Ventas totales de productos | 12,177 | 15 | 18 | 4,827 | 19 | 3,702 | 18 | 26 | 2,503 | 18 | 16 | 1,145 | (7) | 1 |
Mesa 24: Ingresos de la Alianza
Q1 2024 | Q1 2023 | ||
$m | $m | ||
Enhertu | 339 | 220 | |
Tezspire | 77 | 43 | |
beyfortus | 20 | - | |
Otros ingresos de la Alianza | 21 | 23 | |
Total | 457 | 286 |
Mesa 25: Ingresos de colaboración
Q1 2024 | Q1 2023 | ||
$m | $m | ||
Farxiga: hitos de ventas | 45 | 24 | |
Otros ingresos por colaboración | - | 3 | |
Total | 45 | 27 |
Mesa 26: Otros ingresos y gastos de explotación
Q1 2024 | Q1 2023 | ||
$m | $m | ||
financiación de la terminación de la licencia de brazikumab | - | 38 | |
Desinversión de los derechos estadounidenses a Pulmicort flexhaler | - | 241 | |
Otro | 67 | 100 | |
Total | 67 | 379 |
Otra información del accionista
Calendario financiero
Announcement of H1 and Q2 2024 results: 25 July 2024
Announcement of 9M and Q3 2024 results: 12 November 2024
Los dividendos normalmente se pagan de la siguiente manera:
First interim: announced with the half year results and paid in September
Second interim: announced with full year results and paid in March
Contacto
Para obtener detalles sobre cómo ponerse en contacto con el equipo de relaciones con inversores, haga clic aquí. Para contactos de medios, haga clic aquí.
Direcciones para correspondencia
|
|
| |
Oficina registrada | Oficina de registro y transferencia | Depositario central de valores sueco | Depositario de EE. UU. Deutsche Bank Trust Company Américas |
Avenida Francisco Crick, 1 Campus biomédico de Cambridge Cambridge CB2 0AA | Equiniti limitada Casa de aspecto camino de spencer Punción West Sussex BN99 6DA | Euroclear Suecia AB PO Box 191 SE-101 23 Estocolmo | Transferencia de acciones americanas 6201 15th Avenue Brooklyn NY 11219
|
Reino Unido | Reino Unido | Suecia | Estados Unidos |
+44 0 20 3749 5000 | 0800 389 1580 | +46 0 8 402 9000 | +1 (888) 697 8018 |
+44 0 121 415 7033 | +1 (718) 921 8137 | ||
|
Marcas Comerciales
Trademarks of the AstraZeneca group of companies appear throughout this document in italics. Medical publications also appear throughout the document in italics. AstraZeneca, the AstraZeneca logotype and the AstraZeneca symbol are all trademarks of the AstraZeneca group of companies. Trademarks of companies other than AstraZeneca that appear in this document include: FasT CAR owned by Gracell Biotechnology, Co., Ltd.; Plendil owned by AstraZeneca or Glenwood GmbH (depending on geography); Beyfortus, una marca registrada de Sanofi Pasteur Inc.; Enhertu, una marca comercial de Daiichi Sankyo; seloken, propiedad de AstraZeneca o Taiyo Pharma Co., Ltd (según la geografía); Synagis, propiedad de AstraZeneca o Sobi, también conocida como Swedish Orphan Biovitrum AB (publ). (dependiendo de la geografía); y Tezspire, una marca registrada de Amgen, Inc..
Información en o accesible a través de los sitios web de AstraZeneca, incluyendo astrazeneca.com, no forma parte ni se incorpora a este anuncio.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Visite a astrazeneca.com y sigue a la Compañía en las Redes Sociales @AstraZeneca.
Declaraciones de precaución con respecto a las declaraciones prospectivas
Para, entre otras cosas, utilizar las disposiciones de 'puerto seguro' de la Ley de Reforma de Litigios de Valores Privados de EE. UU. De 1995, AstraZeneca (en adelante, 'el Grupo') proporciona la siguiente declaración de advertencia:
Este documento contiene ciertas declaraciones prospectivas con respecto a las operaciones, desempeño y condición financiera del Grupo, incluyendo, entre otras cosas, declaraciones sobre ingresos esperados, márgenes, ganancias por acción u otras medidas financieras o de otro tipo. Aunque el Grupo cree que sus expectativas se basan en suposiciones razonables, cualquier declaración prospectiva, por su propia naturaleza, implica riesgos e incertidumbres y puede estar influenciada por factores que podrían causar que los resultados reales y los resultados sean materialmente diferentes de los pronosticados. Las declaraciones prospectivas reflejan el conocimiento y la información disponible en la fecha de preparación de este documento y el Grupo no asume ninguna obligación de actualizar estas declaraciones prospectivas. El Grupo identifica las declaraciones prospectivas utilizando las palabras "anticipa", "cree", "espera", "pretende" y expresiones similares en dichas declaraciones. Los factores importantes que podrían causar que los resultados reales difieran materialmente de los contenidos en las declaraciones prospectivas, algunas de las cuales están fuera del control del Grupo, incluyen, entre otras cosas:
- el riesgo de falla o retraso en la entrega del oleoducto o el lanzamiento de nuevos medicamentos
- el riesgo de no cumplir con los requisitos regulatorios o éticos para el desarrollo de medicamentos o aprobación
- el riesgo de fallos o retrasos en la calidad o ejecución de las actividades comerciales del Grupo estrategias
- el riesgo de fijación de precios, asequibilidad, acceso y competitividad presiones
- el riesgo de no mantener el suministro de productos de calidad y conformes medicamentos
- el riesgo de comercio ilegal en los activos del Grupo medicamentos
- el impacto de la dependencia de bienes de terceros y xDSL
- el riesgo de fracaso en la tecnología de la información o la seguridad cibernética
- el riesgo de fallo de críticos en costes
- el riesgo de no recopilar y gestionar datos de acuerdo con los requisitos legales y reglamentarios y las estrategias ,
- el riesgo de no atraer, desarrollar, involucrar y retener a una población diversa, talentosa y capaz personal
- el riesgo de no cumplir con las expectativas regulatorias o éticas sobre el impacto ambiental, incluido el climático el cambio
- el riesgo de que se vea afectada la seguridad y eficacia de los medicamentos comercializados. cuestionado
- el riesgo de resultados adversos de litigios y/o decisiones gubernamentales. las investigaciones
- intellectual property-related risks to the Group's productos
- el riesgo de no lograr planes estratégicos o cumplir objetivos o las expectativas
- el riesgo de falla en el control financiero o la ocurrencia de fraude
- el riesgo de deterioro inesperado de la situación financiera del Grupo posición
- el impacto que los acontecimientos globales y/o geopolíticos pueden tener o seguir teniendo sobre estos riesgos, sobre la capacidad del Grupo para continuar mitigándolos y sobre las operaciones, los resultados financieros o la situación financiera del Grupo
There can be no guarantees that the conditions to the closing of the proposed transaction with Fusion will be satisfied on the expected timetable or at all or that "FPI-2265" (Ac225-PSMA I&T) or any combination product will receive the necessary regulatory approvals or prove to be commercially successful if approved. There can be no guarantees that the conditions to the closing of the proposed transaction with Amolyt Pharma will be satisfied on the expected timetable or at all or that eneboparatide ("AZP-3601") will receive the necessary regulatory approvals or prove to be commercially successful if approved.
Glosario
1L, 2L, etc First line, second line, etc
ADC Antibody drug conjugate
aHUS Atypical haemolytic uraemic syndrome
AKT Protein kinase B
AL amyloidosis Light chain amyloidosis
ANDA Abbreviated New Drug Application (US)
ASO Antisense oligonucleotide
ATTR-CM Transthyretin-mediated amyloid cardiomyopathy
ATTRv / -PN / -CM Hereditary transthyretin-mediated amyloid / polyneuropathy / cardiomyopathy
BCMA B-cell maturation antigen
BRCA / m Breast cancer gene / mutation
BTC Biliary tract cancer
BTK Bruton tyrosine kinase
C5 Complement component 5
CAR-T Chimeric antigen receptor T-cell
cCRT Concurrent chemoradiotherapy
CD19 A gene expressed in B-cells
CER Constant exchange rates
CHMP Committee for Medicinal Products for Human Use (EU)
CI Confidence interval
CKD Chronic kidney disease
CLL Chronic lymphocytic leukaemia
COPD Chronic obstructive pulmonary disease
COP28 28.ª reunión anual sobre el clima de las Naciones Unidas (ONU)
CRC Colorectal cancer
CRL Compete Response Letter
CRPC Castration-resistant prostate cancer
CSPC Castration-sensitive prostate cancer
CTLA-4 Cytotoxic T-lymphocyte-associated antigen 4
CVRM Cardiovascular, Renal and Metabolism
DDR DNA damage response
DNA Deoxyribonucleic acid
EBITDA Earnings before interest, tax, depreciation and amortisation
EGFR / m Epidermal growth factor receptor / mutation
EGPA Eosinophilic granulomatosis with polyangiitis
EPS Earnings per share
ERBB2 v-erb-b2 avian erythroblastic leukaemia viral oncogene homologue 2
EVH Extravascular haemolysis
FDA Food and Drug Agency (US)
FDC Fixed dose combination
g Germline, e.g. gBRCAm
GAAP Generally Accepted Accounting Principles
GEJ Gastro oesophageal junction
GI Gastrointestinal
GLP1 / -RA Glucagon-like peptide-1 / receptor agonist
gMG Generalised myasthenia gravis
HCC Hepatocellular carcinoma
HER2 / +/- / low / m Human epidermal growth factor receptor 2 / positive / negative / low level expression / mutant
HF/ pEF / rEF Heart failure / with preserved ejection fraction / with reduced ejection fraction
hMPV Human metapneumovirus
HR / + / - Hormone receptor / positive / negative
HRD Homologous recombination deficiency
HRRm Homologous recombination repair gene mutation
i.m. Intramuscular injection
i.v. Intravenous injection
IAS / B International Accounting Standards / Board
ICS Inhaled corticosteroid
IFRS International Financial Reporting Standards
IgAN Immunoglobulin A neuropathy
IHC Immunohistochemistry
IL-5, IL-33, etc Interleukin-5, Interleukin-33, etc
IP Intellectual Property
IVIg Intravenous immune globulin
LABA Long-acting beta-agonist
LAMA Long-acting muscarinic-agonist
LS-SCLC Limited stage small cell lung cancer
LRTD Lower respiratory tract disease
m Metastatic, e.g. mBTC , mCRPC, mCSPC
mAb Monoclonal antibody
MDL Multidistrict litigation
MET Mesenchymal epithelial transition
NF1-PN Neurofibromatosis type 1 with plexiform neurofibromas
n/m Not meaningful
NMOSD Neuromyelitis optica spectrum disorder
NRDL National reimbursement drug list
NSCLC Non-small cell lung cancer
OECD Organisation for Economic Co-operation and Development
OOI Other operating income
ORR Overall response rate
OS Overall survival
PARP / i / -1sel Poly ADP ribose polymerase / inhibitor /-1 selective
pCR Pathologic complete response
PCSK9 Proprotein convertase subtilisin/kexin type 9
PD Progressive disease
PD-1 Programmed cell death protein 1
PD-L1 Programmed cell death ligand 1
PDUFA Prescription Drug User Fee Act
PHSSR Partnership for Health System Sustainability and Resilience
PFS Progression free survival
PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha
PMDI Pressure metered dose inhaler
PNH / -EVH Paroxysmal nocturnal haemoglobinuria / with extravascular haemolysis
PPI Proton pump inhibitors
PSR Platinum sensitive relapse
PTEN Phosphatase and tensin homologue
Q3W, Q4W, etc Every three weeks, every four weeks, etc
R&D Research and development
R&I Respiratory & Immunology
RSV Respiratory syncytial virus
sBLA Supplemental biologics license application (US)
SCLC Small cell lung cancer
s.c. Subcutaneous injection
SEA Severe eosinophilic asthma
SEC Securities Exchange Commission (US)
SG&A Sales, general and administration
SGLT2 Sodium-glucose cotransporter 2
SLL Small lymphocytic lymphoma
SMI Sustainable Markets Initiative
SPA Share Purchase Agreement
T2D Type-2 diabetes
TACE Transarterial chemoembolization
THP A treatment regimen: docetaxel, trastuzumab and pertuzumab
TNBC Triple negative breast cancer
TNF Tumour necrosis factor
TOP1 Topoisomerase I
TROP2 Trophoblast cell surface antigen 2
USPTO US Patent and Trademark Office
V&I Vaccines & Immune Therapies
VBP Volume-based procurement
VLP Virus like particle
- Fin del documento -
[ 1 ] Tipos de cambio constantes. Las diferencias entre el cambio real y el cambio CER se deben a movimientos cambiarios entre períodos de 2024 y 2023. Las medidas financieras CER no se contabilizan de acuerdo con los principios de contabilidad generalmente aceptados (GAAP) porque eliminan los efectos de los movimientos monetarios de los resultados informados.
[ 2 ] Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Table 11 in the Financial performance section of this document.
[ 3 ] The calculation of Reported and Core Product Sales Gross Margin excludes the impact of Alliance Revenue and Collaboration Revenue.
[ 4 ] In Table 2, the plus and minus symbols denote the directional impact of the item being discussed, e.g. a '+' symbol next to a comment related to the R&D expense indicates that the item resulted in an increase in the R&D spend relative to the prior year.
[ 5 ] Los ingresos por enajenaciones de activos y negocios, en los que el Grupo no retiene un interés económico significativo en curso, continúan registrándose en Otros ingresos y gastos operativos en los estados financieros de la Compañía.
[ 6 ] The presentation of Table 4 has been updated to show Total Revenue by medicine, by including Alliance Revenue and Collaboration Revenue within each revenue figure. Previously, this table showed Product Sales for each medicine and therapy area, and the Company's total Alliance Revenue and Collaboration Revenue were shown as separate lines at the bottom of the table.
[ 7 ] The presentation of this table has been updated by removing the "Acquisition of Alexion" column due to immateriality of items in this category
[ 8 ] Basado en las mejores suposiciones predominantes en torno a los perfiles de divisas.
[ 9 ] Basado en tarifas spot diarias promedio del 1 de enero de 2023 al 31 de diciembre de 2023.
[ 10 ] Based on average daily spot rates 1 Jan 2024 to 31 Mar 2024.
[ 11 ] Based on average daily spot rates 1 Mar 2024 to 31 Mar 2024.
[ 12 ] Otras monedas incluyen AUD, BRL, CAD, KRW y RUB.
[ 13 ] La tabla proporciona un análisis de las ventas de productos interanuales, con tasas de crecimiento reales y de CER que reflejan el crecimiento interanual. Debido al redondeo, la suma de varios valores en dólares y porcentajes puede no coincidir con los totales.
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.